

Jean-Marc SABATIER

Tel No : 00 33 6 40 15 24 19 (cellular)
Fax No : 00 33 4 42 29 16 12
Email : sabatier.jm1@libertysurf.fr
sabatier.jm1@gmail.com
Orcid : <https://orcid.org/0000-0002-9040-5647>

Qualified : DOCTOR IN BIOCHEMISTRY
 HABILITATION A DIRIGER DES RECHERCHES (HDR)

Expertise :

- *Drug design and synthesis (peptides and related compounds) ;*
- *Optimization of peptide structure/conformation (to improve bioactivity, selectivity, solubility, and/or stability) ;*
- *Peptide and protein engineering ;*
- *Development of peptide-based in vitro assays (diagnostic tests, etc.) ;*
- *Toxinology ;*
- *Evaluation of research projects.*

Achievements :

2023-24 Research Fellow at the INTI International University (Malaysia).

2012 Award of the best scientific advance, *XVIIème Rencontres Transfrontalières Capteurs et Biocapteurs*, Tarragona (Spain), 2012.

2003 Award of best communication, 5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires, France.

1998-06 Four « Prix de Thèse » for my Ph.D students, Université de la Méditerranée.

1996 Achievement Award (ABI, Raleigh, US).

1995 International Man of the Year Award (IBC, Cambridge, UK).

Neosystem Award for the most distinguished work on structure-activity relationship studies of peptides, 9th Peptides & Proteins Meeting, Aussois (France).

1993 Citizen of the Year Award (Nouvel Economiste, France) for the design and chemical synthesis of SPC3, a multibranched peptide construction with anti-HIV activity.

Professional membership :

2006-2012 President of one of the seven societies (Venom Peptide Group) constituting The International Neuropeptide Society.

1989-present The International Neuropeptide Society; The New-York Academy of Sciences; American Society for Microbiology; American Peptide Society (charter member); American Society for Biochemistry and Molecular Biology (on behalf of the editor of J. Biol. Chem.); Biochemical Society (on behalf of the editor of The Biochemical Journal); Federation of American Societies for Experimental Biology; European

Peptide Society; International Society on Toxinology; Société Française des Peptides et des Protéines; Société Française de Biochimie et Biologie Moléculaire; Société Française de Microbiologie; Groupement d'étude des polypeptides actifs; Association pour la Promotion de la Recherche en Interactions Cellulaires.

Detailed scientific publications :**- EDITION OF BOOKS & SPECIAL ISSUES**
(published = 36)

Guest Editor of a special issue (2023) of the journal « *Frontiers in Pharmacology* » titled « Reviews in pharmacology of ion channels and channelopathies 2023 » (Frontiers media).

Guest Editor of a special issue (2023) of the journal « *Molecules* » titled « Medicinal Chemistry in Europe IV » (MDPI - Open Access Publishing).

Guest Editor of a special issue (2022) of the journal « *Frontiers in Pharmacology* » titled « Structure and functional venomomics as a powerful approach for drug discovery and development » (Frontiers media).

Guest Editor of a special issue (2022) of the journal « *Antibiotics* » titled « Reviews on antimicrobial peptides » (MDPI - Open Access Publishing).

Guest Editor of a special issue (2022) of the journal « *Molecules* » titled « Bioactive molecules in SARS-CoV-2 infection and Covid-19 » (MDPI - Open Access Publishing).

Guest Editor of a special issue (2021) of the journal « *Antibiotics* » titled « 10th anniversary of *Antibiotics* – Recent advances in antimicrobial peptides » (MDPI - Open Access Publishing).

Guest Editor of a special issue (2021) of the journal « *Frontiers in Pharmacology* » titled « Venoms, animal and microbial toxins, volume II » (Frontiers media).

Guest Editor of a special issue (2021) of the journal « *Molecules* » titled « Medicinal Chemistry in Europe III » (MDPI - Open Access Publishing).

Guest Editor of a special issue (2021) of the journal « *Marine Drugs* » titled « Ion channels as marine drug targets 2021 » (MDPI - Open Access Publishing).

Guest Editor of a special issue (2021) of the journal « *Sci* » titled « Natural extracts and bioactive derivatives: strategies for biopharmaceutical uses » (MDPI - Open Access Publishing).

Guest Editor of a special issue (2020) of the journal « *Frontiers in Pharmacology* » titled « Venoms, animal and microbial toxins » (Frontiers media).

Guest Editor of a special issue (2020) of the journal « *Antibiotics* » devoted to the peptide antibiotics from microbes and venomous animals (MDPI - Open Access Publishing).

Guest Editor of a special issue (2020) of the journal « *Marine Drugs* » devoted to the ion channels as marine drug targets (MDPI - Open Access Publishing).

Guest Editor of a special issue (2019) of the « *Journal of Unexplored Medical Data* » devoted to the animal venom compounds and their derivatives as candidate therapeutic drugs (OAE Publishing Inc.).

Guest Editor of a special issue (2019) of the journal « *Antibiotics* » devoted to the antibacterial peptides (MDPI - Open Access Publishing).

Guest Editor of a special issue (2019) of the journal « *Molecules* » devoted to the natural toxins/molecules (and derivatives) from animal venoms: from basic research to therapeutic applications (MDPI - Open Access Publishing).

Guest Editor of a special issue (Volume 23, 2018) of the journal « *Molecules* » devoted to the natural toxins/molecules (and derivatives) from animal venoms: from basic research to therapeutic applications (MDPI - Open Access Publishing).

Guest Editor of a special issue (Volume 22, 2017) of the journal « *Molecules* » devoted to the structure-activity relationship of natural products (MDPI - Open Access Publishing).

Guest Editor of a special issue (Volume 9, 2009) of the U.S. journal « *Infectious Disorders - Drug Targets* » devoted to drug targets in viral infections (Bentham Science Publishers).

Guest Editor of two special issues (2009 & 2010) of the journal « *Molecules* » devoted to Toxins - Organic and Analytical Chemistry (MDPI - Open Access Publishing).

Guest Editor of a special issue (2009) of the journal « *Toxins* » devoted to Animal Venoms (MDPI - Open Access Publishing).

Guest Editor of a special issue (2011) of the journal « *Inflammation and Allergy - Drug Targets* » entitled « *Immunological responses to animal venom toxins and their potential value in therapy* » (Bentham Science Publishers).

Guest Editor of a special issue (2014) of the journal « *Toxins* » devoted to Ion Channel Neurotoxins (MDPI - Open Access Publishing).

Guest Editor of a special issue « *Ion Channels as Marine Drug Targets* ».
Book of *Marine Drugs*, MDPI Publisher (2020).

Guest Editor of a special issue « *Ion Channels as Marine Drug Targets* ».
Special issue of *Marine Drugs*, MDPI Publisher (2018-19).

Guest Editor of a special issue « *Natural toxins/molecules (and derivatives) from animal venoms: from basic research to therapeutic applications* ».
Special issue of *Molecules*, MDPI Publisher (2019).

Guest Editor of a special issue « *Natural toxins/molecules (and derivatives) from animal venoms: from basic research to therapeutic application* »s.
Special issue of *Molecules*, MDPI Publisher (2018).

Guest Editor of a special issue « *Structure-Activity Relationship of Natural Products* ».
Special issue of *Molecules*, MDPI Publisher (2017).

Guest Editor of a special issue « *Ion Channel Neurotoxins* ».
Special issue of *Toxins*, MDPI Publisher (2014).

Guest Editor of a special issue « *Animal Venom Toxins and their Therapeutic Applications* ».
Special issue of *Inflammation and Allergy – Drug Targets*, Bentham Science Publishers (2011).

Guest Editor of a special issue « *Drug Targets in Viral Infections* ».
Special issue of *Infectious Disorders - Drug Targets*, Bentham Science Publishers (2009).

Guest Editor of a special issue « *Animal Venoms* ».
Special issue of *Toxins*, MDPI Publisher (2009).

Section Editor for book sections on venom peptides: « *Handbook of Biologically-Active Peptides* ».
1st and 2nd Editions, Elsevier Publishers (2006 & 2012).

Editor of a book « *Animal Toxins and Potassium Channels* ».
Perspectives in Drug Discovery and Design, Vols. 15/16, Kluwer Academic Publishers (1999).

Editor of a book « *HIV Infection in CD4⁺ cells* ».
Perspectives in Drug Discovery and design, Vol. 5, Escom Science Publishers (1996).

- BOOK CHAPTERS
(published = 4)

Animal Toxins in the World of Modern Biotechnologies.
Sabatier, J.-M., De Waard, M., « *Handbook of Biologically-Active Peptides*», 2nd Edition, Kastin A. Ed., Elsevier Publishers (2012).

Structure-Function Strategies to Improve the Pharmacological Value of Animal Toxins.

De Waard, M., Sabatier, J.-M., « *Handbook of Biologically-Active Peptides* », Kastin A. Ed., Elsevier Publishers (2006).

Methodological Approaches to the Study of Ion Channels using Peptide Toxins : Proposed Comprehensive Guidelines.

De Waard, M., Sabatier, J.-M., Rochat, H., « *Perspectives in Molecular Toxinology* », Ménez A. Ed., John Wiley & Sons Ltd., pp 255-269 (2002).

Chemical Synthesis and Characterization of Small Proteins: Example of Scorpion Toxins.

Sabatier, J.-M., *Handbook of Toxinology, "Animal Toxins: Tools in Cell Biology"*, Chapman & Hall, Birkhäuser Verlag Basel/Switzerland, pp 196-216 (2000).

- ARTICLES: specialised journals
(published = 249)

24-1 The possible role of nuclear factor erythroid-2-related factor 2 activators in the management of Covid-19.

Al-Kuraishy, H.M., Al-Gareeb, A.I., Eldahshan, O.A., Abdelkhalek, Y.M., Eldahshan, M., Ahmed, E.A., Sabatier, J.-M., El-Saber Bathila, G., *Journal of Biochemical and Molecular Toxicology* (2023). Doi: 10.1002/jbt.23605

24-2 The unsuspected role of the renin-angiotensin system (RAS): could its dysregulation be at the root of all non-genetic human diseases?

Fajloun, Z., Sabatier, J.-M., *Infectious Disorders-Drug Targets* (2024). Doi: 10.2174/1871526524666230914524

24-3 Treating COVID-19 with medicinal plants: is it even conceivable? A comprehensive review.

Al-Jamal, H., Idriss, S., Roufayel, R., Abi Khattar, Z., Fajloun, Z., Sabatier, J.-M., *Viruses*, 16(3), 320 (2024). Doi: 10.3390/v16030320

24-4 The intriguing connection between cholestasis and the renin-angiotensin system dysregulation induced by SARS-CoV-2 and/or the vaccinal spike protein.

Fajloun, Z., Khattar, Z.A., Sabatier, J.-M., *Infectious Disorders-Drug Targets* (2024). Doi: 102174/0118715265304515240220105152

24-5 Vitamin D and mitochondrial activity preservation in COVID-19.

Giacomoni, J., Sabatier, J.-M., *Infectious Disorders-Drug Targets* (2024). Doi: 10.2174/0118715265304580240405064250

24-6 Structural and functional venomics as a powerful approach for drug discovery and development.

Abdel-Rahman, M.A., Cao, Z., Abd El-Aziz, Styrong, P.N., Sabatier, J.-M., *Frontiers in Pharmacology* (2024). Doi: 10.3389/fphar.2024.1405681

24-7 Renin-angiotensin system dysregulation: ADAM17 activation consequences related to SARS-CoV-2.

Giacomoni, J., Sabatier, J.-M., *Infectious Disorders-Drug Targets* (2024). Doi: 10.2174/0118715265299597240422102455

24-8 Neuroarchitecture: how the perception of our surroundings impacts the brain.

Abbas, S., Okdeh, N., Roufayel, R., Kovacic, H., Sabatier, J.-M., Fajloun, Z., Abi Khattar, Z., *Biology*, **13**(4), 220 (2024). Doi: 10.3390/biology13040220

24-9 SARS-CoV-2 or vaccinal spike protein can induce mast cell activation syndrome (MCAS).

Fajloun, Z., Khattar, Z.A., Sabatier, J.-M., *Infectious Disorders-Drug Targets* (2024). Doi: 10.2174/0118715265319896240427045026

23-1 Phytochemical constituents, folk medicinal uses, and biological activities of genus *Angelica*: a review.

El-Saber Bathila, G., Shaheen, H.M., Elhawary, E.A., Mostafa, N.M., Eldahshan, O.A., Sabatier, J.-M., *Molecules*, **28**, 267 (2023). Doi: 10.3390/molecules28010267

23-2 COVID-19 and Ehlers-Danlos syndrome: the dangers of the Spike protein of SARS-CoV-2.

Fajloun, Z., Legros, C., Sabatier, J.-M., *Infectious Disorders-Drug Targets*, (2023). Doi: 10.2174/1871526523666230104145108

23-3 Why can high-level athletes develop very severe or fatal forms after intense exercise following SARS-CoV-2 infection or anti-Covid vaccination?

Fajloun, Z., Khattar, Z.A., Kovacic, H., Legros, C., Sabatier, J.-M., *Infectious Disorders-Drug Targets*, (2023). Doi: 10.2174/1871526523666230111104355

23-4 Isolation and molecular characterization of *Corynebacterium pseudotuberculosis*: association with proinflammatory cytokines in caseous lymphadenitis pyogranulomas.

Torky, H.A., Saad, H.M., Khaliel S.A., Kassih, A.T., Sabatier, J.-M., El-Saber Bathila, G., Hetta, H.F., Elghazaly, E.M., De Waard, M., *Animals*, **13**(2), 296 (2023). Doi: 10.3390/ani13020296

23-5 Emergence of gloomy eyelet inside DNA.

Sabatier, J.-M., Amini, F., *Biophysica*, **3**, 35-45 (2023). Doi: 10.3390/biophysica3010003

23-6 Identifying the geographic distribution pattern of venomous reptiles and regions of high snakebite risk in Iran.

Kazemi, S.M., Hosseinzadeh, M.S., Sabatier, J.-M., *Animals* (2023). In press.

23-7 Protective role and functional engineering of neuropeptides in depression and anxiety: an overview.

Okdeh, N., Mahfouz, G., Harb, J., Sabatier, J.-M., Roufayel, R., Hanna, E.G., Kovacic, H., Fajloun, Z., *Bioengineering*, **10**(2), 258 (2023). Doi: 10.3390/bioengineering10020258

23-8 Overexpression of a novel *Noxo1* mutant increases *Ros* production and *Noxo1* relocalisation.

Benssouina, F.Z., Parat, F., Villard, C., Leloup, L., Garrouste, F., Sabatier, J.-M., Ferhat, L., Kovacic, H., *Int. J. Mol. Sci.*, **24**(5), 4663 (2023). Doi: 10.3390/ijms24054663

23-9 SIBO: the trail of a new human pathology associated with multiple severe and disabling Covid-19 and long Covid symptoms or induced by the anti-Covid-19 vaccine.

Fajloun, Z., Khattar, Z.A., Kovacic, H., Legros, C., Sabatier, J.-M., *Infectious Disorders-Drug Targets*, (2023). Doi: 10.2174/1871526523666230210162334

23-10 ***Understanding and relieving of neuropathic disorders in the long Covid.***

Fajloun, Z., Khattar, Z.A., Kovacic, H., Legros, C., [Sabatier, J.-M.](#), *Infectious Disorders-Drug Targets*, (2023).
Doi: 10.2174/1871526523666230227113205

23-11 ***Anti-Covid-19 vaccination, Covid-19, and female contraception: the exacerbated risk (thromboembolism) of the estrogen-progestin pill.***

Fajloun, Z., Khattar, Z.A., Kovacic, H., Legros, C., [Sabatier, J.-M.](#), *Infectious Disorders-Drug Targets*, (2023).
Doi: 10.2174/1871526523666230224094439

23-12 ***Inhibitors of ATP synthase as new antibacterial candidates.***

Mackieh, R., Al-Bakkar, N., Kfoury, M., Roufayel, R., [Sabatier, J.-M.](#), Fajloun, Z., *Antibiotics*, 12, 650 (2023).
Doi: 10.3390/antibiotics12040650

23-13 ***Inhibition mechanism of methicillin-resistant Staphylococcus aureus by zinc oxide nanorods via suppresses penicillin-binding protein 2a.***

Hassan, A., Al-Salmi, F.A., Saleh, M.A., [Sabatier, J.-M.](#), Alatawi, F.A., Alenezi, M.A., Albalwe, F.M., Albalawi, H.M., Darwish, D.B., Sharaf, E.M., *ACS Omega*, 8(11), 9969-9977 (2023). Doi: 10.1021/acsomega.2c07142

23-14 ***Oxidative stress-induced hormonal disruption in male reproductive organ.***

Rotimi, D., Acho, M.A., Falana, B.M., Olaolu, T.D., Mgbojikwe, I., Althumairy, D., El-Saber Bathila, G., Adeyemi, O., [Sabatier, J.-M.](#), De Waard, M., *Frontiers in Endocrinology*, in press (2023).

23-15 ***Long COVID and risk of erectile dysfunction in recovered patients from mild to moderate COVID-19.***

Al-Kuraishy, H.M., Al-Gareeb, A.I., Alarfaj, S.J., Al-Akeel, R.K., Faidah, H., El-Bouseary, M.M., [Sabatier, J.-M.](#), De Waard, M., El-Masry, T.A., El-Saber Bathila, G., *Scientific Reports*, 13(1), 5977 (2023). Doi: 10.1038/s41598-023-32211-5

23-16 ***COVID-19 and Alzheimer's disease: the link finally established.***

Fajloun, Z., Wu, Y., Cao, Z., Kovacic, H., [Sabatier, J.-M.](#), *Infectious Disorders-Drug Targets*, (2023). Doi: 10.2174/1871526523666230529162633

23-17 ***COVID-19 and Parkinson's disease: the link also established!***

Fajloun, Z., Wu, Y., Cao, Z., Kovacic, H., [Sabatier, J.-M.](#), *Infectious Disorders-Drug Targets*, (2023). Doi: 10.2174/1871526523666230619104142

23-18 ***COVID-19 and anti-Covid-19 vaccination: potential damages to the thyroid gland.***

Fajloun, Z., Abi Khattar, Z., Kovacic, H., [Sabatier, J.-M.](#), *Infectious Disorders-Drug Targets*, (2023). Doi: 10.2174/1871526523666230509112038

23-19 ***Toxicity of SARS-CoV-2 Spike protein from the virus and produced from COVID-19 mRNA or adenoviral DNA vaccines.***

Lesgards, J.-F., Cerdan, D., Perronne, C., [Sabatier, J.-M.](#), Azalbert, X., Rodgers, E.A., McCullough, P.A., *Archives of Microbiology and Immunology*, 7(3), 121-138 (2023).

23-20 **Unlocking the benefits of fasting: a review of its impact on various biological systems and human health.**
Mackieh, R., Al-Bakkar, N., Kfoury, M., Okdeh, N., Pietra, H., Roufayel, R., Legros, C., Fajloun, Z., Sabatier, J.-M., *Current Medicinal Chemistry* (2023). Doi : 10.2174/0109298673275492231121062033

22-1 **The relationship between COVID-19 viral load and disease severity: a systematic review.**

Dadras, O., Afsahi, A.M., Pashaei, Z., Mojdeganlou, H., Karimi, A., Habibi, P., Barezegary, A., Fakhfour, A., Mirzapour, P., Janfaza, N., Dehghani, S., Afroughi, F., Dashti, M., Khodaei, S., Mehraeen, E., Voltarelli, F., Mehrtak, M., Mohssenipour, M. Moradmamand-Badie, B., Heydari, M., Sabatier, J.-M., Alinaghi, S.A., *Immunity, Inflammation and Disease*, 10(3):e580 (2022). Doi: 10.1002/iid3.580

22-2 **Impact of COVID-19 pandemic on routine vaccination coverage of children and adolescents: a systematic review.**

Alinaghi, S.A., Karimi, A., Mojdeganlou, H., Alilou, S., Mirghaderi, S.P., Noori, T., Shamsabadi, A., Dadras, O., Vahedi, F., Mohammadi, P., Shojaei, A., Mahdiabadi, S., Janfaza, N., Lonbar, A.K., Mehraeen, E., Sabatier, J.-M., *Health Science Reports* 5(2): e00516 (2022). Doi: 10.1002/hsr2.516

22-3 **Angiotensin II Type I receptor (AT1R): the gate towards COVID-19-associated diseases.**

El-Arif, G., Khazaal, S., Farhat, A., Harb, J., Annweiler, C., Wu, Y., Cao, Z., Kovacic, H., Abi Khattar, Z., Fajloun, Z., Sabatier, J.-M., *Molecules*, 27(7), 2048 (2022). Doi: 10.3390/molecules27072048

22-4 **Discovery of Leptulipin, a new anticancer protein from the Iranian scorpion, Hemiscorpius lepturus.**

Rezaei, A., Asgari, S., Komijani, S., Sadat, S.N., Sabatier, J.-M., Bagheri, K.P., Shahbazzadeh, D., Akbari Eidgahi, M.R., De Waard, M., Mirzahoseini, H., *Molecules*, 27(7), 2056 (2022). Doi: 10.3390/molecules27072056

22-5 **Parkinson disease: protective role and function of neuropeptides.**

Tabikh, M., Chahla, C., Okdeh, N., Kovacic, H., Sabatier, J.-M., Fajloun, Z., *Peptides*, 151 :170713 (2022). Doi : 10.1016/j.peptides.2021.170713

22-6 **SARS-CoV-2-induced neurological disorders in symptomatic Covid-19 and long Covid patients: key role of brain renin-angiotensin system.**

Fajloun, Z., Kovacic, H., Annweiler, C., Wu, Y., Cao, Z., Sabatier, J.-M., *Infectious Disorders-Drug Targets*, 22(5), 3-5 (2022). Doi: 10.2174/1871526522666220406124618.

22-7 **The pathophysiology of long COVID throughout the renin-angiotensin system.**

Khazaal, S., Harb, J., Rima, M., Annweiler, C., Wu, Y., Cao, Z., Abi Khattar, Z., Legros, C., Kovacic, H., Fajloun, Z., Sabatier, J.-M., *Molecules*, 27(9), 2903 (2022). Doi: 10.3390/molecules27092903

22-8 **Current treatments and therapeutic options for COVID-19 patients: a systematic review.**

Mehraeen, E., Najafi, Z., Hayati, B., Javaherian, M., Rahimi, S., Dadras, O., Alinaghi, S.A., Ghadimi, M., Sabatier, J.-M., *Infectious Disorders-Drug Targets*, 22(1):e260721194968 (2022). Doi: 10.2174/187152652166621072650435

22-9 **DAMPening severe Covid-19 with Dexamethasone.**

Annweiler, C., Papon, N., Sabatier, J.M., Barré, J. *Infectious Disorders-Drug Targets*, 22(2):e270821195910, (2022). Doi: 10.2174/1871526521999210827142839

22-10 Vaccines for COVID-19: a review of feasibility and effectiveness.

Mehraeen, E., Dadras, O., Afsahi, A.M., Karimi, A., Mohssenipour, M., Mirzapour, P., Barzegari, A., Behnezhad, F., Habibi, P., Salehi, M.A., Vahedi, F., Heydari, M., Kianzad, S., Moradmand-Badie, B., Javaherian, M., SeyedAlinaghi, S., Sabatier, J.M. *Infectious Disorders-Drug Targets*, 22(2):e230921196758, (2022). Doi: 10.2174/1871526521666210923144837

22-11 Shared food, meals and drinks: 10 arguments suggesting an oral transmission route of SARS-CoV-2.

Wendling, J.-M., Saulnier, A., Sabatier, J.M., *Infectious Disorders-Drug Targets*, 22(2):e160721194830, (2022). Doi: 10.2174/1871526521666210716110603

22-12 Counter-regulatory renin-angiotensin system: an important line of research to understand and limit the severity of COVID-19.

Annweiler, C., Cao, Z., Papon, N., Kovacic, H., Sabatier, J.M. *Infectious Disorders-Drug Targets*, 22(2):e100921196331, (2022). Doi: 10.2174/1871526521666210910063227

22-13 Neuro- and cardiovascular activities of *Montivipera bornmuelleri* snake venom.

Sahyoun, C., Krezel, W., Mattei, C., Sabatier, J.-M., Legros, C., Fajloun, Z., Rima, M., *Biology*, 11(6), 888 (2022). Doi: 10.3390/biology11060888

22-14 Structural dynamics of the SARS-CoV-2 spike protein: a 2-year retrospective analysis of SARS-CoV-2 variants (from alpha to omicron) reveals an early divergence between conserved and variable epitopes.

Guérin, P., Yahi, N., Azzaz, F., Chahinian, H., Sabatier, J.-M., Fantini, J., *Molecules*, 27(12), 3851 (2022). Doi : 10.3390/molecules27123851

22-15 Fast killing kinetics, significant therapeutic index, and high stability of melittin-derived antimicrobial peptide.

Akbari, R., Hakemi-Vala, M., Sabatier, J.-M., Pooshang-Bagheri, K., *Amino acids*, 54(9), 1275-1285 (2022). Doi : 10.1007/s00726-022-03180-2

22-16 Editorial: Venoms, animal and microbial toxins, Volume II.

Cao, Z., Shahbazzadeh, D., Kovacic, H., McNutt, P.M., Wang, J.-L., Wulff, H., Utkin, Y.N., Sabatier, J.-M., *Frontiers in Pharmacology*, 13:973628 (2022). Doi: 10.3389/fphar.2022.973628

22-17 Separation and analytical techniques used in snake venomics: a review article.

Sahyoun, C., Rima, M., Mattei, C., Sabatier, J.-M., Fajloun, Z., Legros, C., *Processes*, 10(7), 1380 (2022). Doi: 10.3390/pr10071380

22-18 SARS-CoV-2, Covid-19, and reproduction: effects on fertility, pregnancy, and neonatal life.

Harb, J., Debs, N., Rima, M., Wu, Y., Cao, Z., Kovacic, H., Fajloun, Z., Sabatier, J.-M., *Biomedicines*, 10(8), 1775 (2022). Doi: 10.3390/biomedicines10081775

22-19 *Rhus coraria* L. (Sumac), a versatile and resourceful food spice with cornucopia of polyphenols.

El-Saber Batiha, G.E., Ogunyemi, O.M., Shaheen, H.M., Kutu, F.R., Olaiya, C.O., Sabatier, J.-M., De Waard, M., *Molecules*, 27(16), 5179 (2022). Doi: 10.3390/molecules27165179

22-20 Role of Neuropilin 1 in COVID-19 patients with acute ischemic stroke.

Al-Thomali, A.W., Al-Kuraishy, H.M., Al-Gareeb, A.I., Al-Buhadiliy, A.K., De Waard, M., Sabatier, J.-M., Khalil, A.A.K., Saad, H.M., El-Saber Bathila, G., *Biomedicines*, 10(8), 2032 (2022). Doi : 10.3390/biomedicines10082032

22-21 The detection of potential native probiotics Lactobacillus spp. Against Salmonella Kentucky ST198 of Lebanese chicken origin.

El Hage, R., El Hage, J., Snini, S.P. Ammoun, I., Touma, J., Rachid, R. Mathieu, F., Sabatier, J.-M., Abi Khattar, Z., El Rayess, Y., *Antibiotics*, 11(9), 1147 (2022). Doi: 10.3390/antibiotics11091147

22-22 The potential role of Growth Differentiation Factor 15 in COVID-19: a corollary subjective effect or not?.

Babalgith, A.O., Al-Kuraishy, H.M., Al-Gareeb, A.I., De Waard, M., Sabatier, J.-M., Saad, H.M., El-Saber Bathila, G., *Diagnostics*, 12(9), 2051 (2022). Doi: 10.3390/diagnostics12092051

22-23 Roxadustat for SARS-CoV-2 infection: old signaling raised new hopes.

Alkazmi, L., Al-Kuraishy, H.M., El-Saber Bathila, G., Mostafa-Hedeab, G., De Waard, M., Sabatier, J.-M., Kabrah, S.M., Saad, H.M., Al-Gareeb, A.I., Simal-Gandara, J., *Drugs in R&D*, 22(3), 183-186 (2022). Doi: 10.1007/s40268-022-00397-0

21-24 Covid-19 in pediatrics: the current knowledge and practice.

Mehraeen, E., Oliaei, S., SeyedAlinaghi, S., Karimi, A., Mirzapour, P., Afsahi, A.M., Barzegari, A., Vahedi, F., Soleymanzadeh, M., Behnezhad, F., Javaherian, M., Zargari, G., Mirghaderi, S.P., Noori, T., Sabatier, J.M., *Infectious Disorders-Drug Targets*, 22(5), 47-57 (2022). Doi: 10.2174/1871526521666210929121705

22-25 Montelukast and acute coronary syndrome: the endowed drug.

Alomair, B.M., Al-Kuraishy, H.M., Al-Gareeb, A.I., Al-Hamash, S.M., De Waard, M., Sabatier, J.-M., Saad, H.M., El-Saber Bathila, G., *Pharmaceuticals*, 15(9), 1147 (2022). Doi: 10.3390/ph15091147

22-26 Statins use in Alzheimer disease: bane or boon from frantic search and narrative review.

Alsubaie, N., Al-Kuraishy, H.M., Al-Gareeb, A.I., Alharbi, B., De Waard, M., Sabatier, J.-M., Saad, H.M., El-Saber Bathila, G., *Brain Sciences*, 12(10), 1290 (2022). Doi: 10.3390/brainsci12101290

22-27 Optimized chemical extraction methods of antimicrobial peptides from roots and leaves of extremophilic plants: Anthyllis sericea and Astragalus armatus collected from the Tunisian desert.

Ben Brahim, R., Ellouzi, H., Fouzai, K., Asses, N., Neffati, M., Sabatier, J.-M., Bulet, P., Regaya, I., *Antibiotics*, 11(10), 1302 (2022). Doi: 10.3390/antibiotics11101302

22-28 The role of Berberine in Covid-19: potential adjunct therapy.

Babalgith, A.O., Al-Kuraishy, H.M., Al-Gareeb, A.I., De Waard, M., Al-Hamash, S.M., Sabatier, J.-M., Ndegm, W.A., El-Saber Bathila, G., *Inflammopharmacology*, (2022). Doi: 10.1007/s10787-022-01080-1

22-29 The Lebanese red algae Jania rubens: promising biomolecules against colon cancer cells.

Rifi, M., Radwan, Z., Al-Monla, R., Fajloun, Z., Sabatier, J.-M., Kouzayha, A., El-Sabban, M., Mawlawi, H., Dassouki, Z., *Molecules*, 27, 6617 (2022). Doi: 10.3390/molecules27196617

22-30 Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: insight from quantum mechanical evaluation and molecular modeling.

Balogun, T.A., Chukwudozie, O.S., Ogbodo, U.C., Junaid, I.O., Sunday, O.A., Ige, O.M., Aborode, A.T., Akintayo, A.D., Oluwarotimi, E.A., Oluwafemi, I.O., Saibu, O.A., Chuckwuemaka, P., Omoboyowa, D.A., Alausa, A.O., Atasie, N.H., Ilesanmi, A., Dairo, G., Tihamiyu, Z.A., Bathila, G.E., Alkhuriji, A.F., Al-Megrin, W.A.I., De Waard, M., Sabatier, J.-M., *Frontiers Chemistry*, 10, 964446 (2022). Doi : 10.3389/fchem.2022.964446

22-31 Phytochemical analysis and understanding the antioxidant and anticancer properties of methanol extract from *Litsea Glutinosa*: in vitro and in vivo studies.

Shafiq, S., Zahan, R., Yesmin, S., Khan, A., Mahmud, M.S., Reza, M.A., Albogami, S.A., Alorabi, M., De Waard, M., Saad, H.M., Sabatier, J.-M., Naz, T., El-Saber Bathila, G.E., *Molecules*, 27, 6964 (2022). Doi : 10.3390/molecules27206964

22-32 Purification and characterization of Bot33: a non-toxic peptide from the venom of *Buthus occitanus tunetanus* scorpion

ElFessi, R., Khamessi, O., Srairi-Abid, N., Sabatier, J.-M., Tytgat, J., Peigneur, S., Kharrat, R., *Molecules*, 27, 7278 (2022). Doi : 10.3390/molecules27217278

22-33 Potential therapeutic benefits of Metformin alone and in combination with Sitagliptin in the management of type 2 diabetes patients with COVID-19.

Al-Kuraishy, H.M., Al-Gareeb, A.I., Albogami, S.M., Sabatier, J.-M., Nadwa, E.H., Hafiz, A.A., Negm, W.A., Kamal, M., Al-Jouboury, M., Elekhaway, E., El-Saber Bathila, G., De Waard, M., *Pharmaceuticals*, 15, 1361 (2022). Doi: 10.3390/ph15111361

22-34 Hypoxia-Inducible Factor 1 and preeclampsia: a new perspective.

Albogami, S.M., Al-Kuraishy, H.M., Al-Maiah, T.J., Al-Buhadily, A.K., Al-Gareeb, A.I., Alorabi, M., Alotaibi, S.S., De Waard, M., Sabatier, J.-M., Saad, H.M., El-Saber Bathila, G., *Current Hypertension Reports* (2022). Doi: 10.1007/s11906-022-01225-1

22-35 The potential role of MUC16 (CA125) biomarker in lung cancer: a magic biomarker but with adversity.

Saad, H.M., Tourky, G.F., Al-Kuraishy, H.M., Al-Gareeb, A.I., Khatlab, A.M., Elmasry, S.A., Alsayegh, A.A., Hakami, Z.H., Alsulimani, A., Sabatier, J.-M., Eid, M.W., Shaheen, H.M., Mohammed, A.A., El-Saber Bathila, De Waard, M., G., *Diagnostics*, 12(12), 2985 (2022). Doi: 10.3390/diagnostics12122985

21-1 Mass spectrometry-based top-down and bottom-up approaches for proteomic analysis of the Moroccan *Buthus occitanus* scorpion venom.

Daoudi, K., Malosse, C., Lafnoute, A., Darkaoui, B., Chakir, S., Sabatier, J.-M., Chamot-Rooke, J., Cadi, R., Oukkache, N., *FEBS Open Bio*. (2021). Doi : 10.1002/2211-5463.13143

21-2 The cytotoxic effect of *Apis mellifera* venom with a synergistic potential of its two main components - Melittin and PLA2- on colon cancer HCT116 cell lines.

Yaacoub, C., Rifi, M., El-Obeid, D., Mawlawi, H., [Sabatier, J.-M.](#), Coutard, B., Fajloun, Z., *Molecules* **26**, 2264 (2021). Doi : 10.3390/molecules26082264

21-3 Fecal metabolic profiling of breast cancer patients during neoadjuvant chemotherapy reveals potential biomarkers.

Zidi, O., Souai, N., Raies, H., Ben Ayed, F., Mezlini, A., Mezrioui, S., Tranchida, F., [Sabatier, J.-M.](#), Mosbah, A., Cherif, A., Shintu, L., Kouidhi, S., *Molecules* **26**, 2266 (2021). Doi : 10.3390/molecules26082266

21-4 Snake venom components: tools and cures to target cardiovascular diseases.

Frangieh, J., Rima, M., Fajloun, Z., Henrion, D., [Sabatier, J.-M.](#), Legros, C., Mattei, C., *Molecules* **26**(8), 2223 (2021). Doi : 10.3390/molecules26082223

21-5 Discovery of a new analgesic peptide, Leptucin, from the Iranian scorpion, Hemiscorpius lepturus.

Bagheri-Ziari, S., Shahbazzadeh, D., Sardari, S., [Sabatier, J.-M.](#), Pooshang-Bagheri, K., *Molecules* **26**, 2580 (2021). Doi: 10.3390/molecules26092580

21-6 Nigella and honey: an efficient treatment against Covid-19?

Wendling, J.-M., [Sabatier, J.-M.](#), Kopferschmitt, J., *Hegel* 2021/1 (N°1), 51-56 (2021). Doi: 10.3917/heg.111.0051

21-7 Editorial: Venoms, animal and microbial toxins.

Cao, Z., Wang, J.-L., McNutt, P.M., Utkin, Y.N., Shahbazzadeh, D., Wulff, H., Kovacic, H., [Sabatier, J.-M.](#), *Frontiers in Pharmacology* (2021). Doi: 10.3389/fphar.2021.706573

21-8 Dairy-derived and egg white proteins in enhancing immune system against COVID-19.

Batiha, G.E., Awad, D.A., Algammal, A.M., Nyamota, R., Wahed, M.I., Shah, M.A., Amin, M.N., Adetuyi, B.O., Hetta, H.H., Cruz-Martins, N., Koirala, N., Ghosh, A., [Sabatier, J.-M.](#), *Frontiers in Nutrition* (2021). Doi : 10.3389/fnut.2021.629440

21-9 Beehive products as antibacterial agents: a review.

Nader R.A., Mackieh, R., Wehbe, R., El Obeid, D., [Sabatier, J.M.](#), Fajloun, Z., *Antibiotics* **10**, 717-741 (2021). Doi: 10.3390/antibiotics10060717

21-10 Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19.

Sun, F., Mu, C., Kwok, H.F., Xu, J., Wu, Y., Liu, W., [Sabatier, J.M.](#), Annweiler, C., Li, X., Cao, Z., Xie, Y., *International Journal of Biological Sciences* **17**(9), 2348-2355 (2021). Doi: 10.7150/ijbs.57810

21-11 Covid-19: is the oral transmission route during shared meals and drinks credible?

Wendling, J.M., Saulnier, A., [Sabatier, J.M.](#), *Virologie* **25**(4), 213-223 (2021). Doi: 10.1684/vir.2021.0910

21-12 Montivipera bornmuelleri venom: inhibitory effect on Staphylococcus epidermidis and Escherichia coli F1F0-ATPases and cytotoxicity on HCT116 cancer cell lines.

Kfoury, M., Mouawad, C., Rifi, M., Sadek, R., [Sabatier, J.M.](#), Nehme, H., Fajloun, Z., *Sci.* **3**, 31 (2021). Doi: 10.3390/sci3030031

21-13 *Current treatments and therapeutic options for Covid-19 patients: a systematic review.*

Mehraeen, E., Najafi, Z., Hayati, B., Javaherian, M., Rahimi, S., Dadras, O., Alinaghi, S.A., Ghadimi, M., Sabatier, J.M., *Infectious Disorders-Drug Targets*, 21, (2021). Doi: 10.2174/1871526521666210726150435

21-14 *Genetic susceptibility of Covid-19: a systematic review of current evidence.*

Alinaghi, S.A., Mehrtak, M., Mohssenipour, M. Mirzapour, P., Barezegary, A., Habibi, P., Moradmamand-Badie, B., Afsahi, A.M., Karimi, A., Heydari, M., Mehraeen, E., Dadras, O., Sabatier, J.M., Voltarelli, F., *Eur. J. Med. Res.*, 26(1), 46 (2021). Doi: 10.1186/s40001-021-00516-8

21-15 *Antimicrobial peptides: a potent alternative to antibiotics.*

Rima, M., Rima, M., Fajloun, Z., Sabatier, J.M., Bechinger, B., Naas, T., *Antibiotics* 10, 1095 (2021). Doi: 10.3390/antibiotics10091095

21-16 *First detection of tobacco mosaic virus in tobacco fields in northern Lebanon.*

Obeid, R., Wehbe, E., Rima, M., Kabara, M., Al Bersaoui, R., Sabatier, J.M., Fajloun, Z., Gereige, D. *Infectious Disorders-Drug Targets*, 21, 534-540 (2021). Doi: 10.2174/1871526520666200928164057

21-17 *Voltage-gated sodium channels: a prominent target of marine drugs.*

Mackieh, R., Abou-Nader, R., Wehbe, R., Mattei, C., Legros, C., Fajloun, Z., Sabatier, J.M., *Marine Drugs*, 19(10), 562 (2021). Doi: 10.3390/md19100562

21-18 *The renin-angiotensin system: a key role in SARS-CoV-2-induced COVID-19.*

El-Arif, G., Farhat, A., Khazaal, S., Annweiler, C., Kovacic, H., Wu, Y., Cao, Z., Fajloun, Z., Abi Khattar, Z., Sabatier, J.M., *Molecules*, 26, 6945 (2021). Doi: 10.3390/molecules26226945

21-19 *Comparison of SARS-CoV-2 (Coronavirus) with other similar viruses based on current evidence.*

Kianzad, S., SeyedAlinaghi, S., Asadollahi-Amin, A., Dadras, O., Karimi, A., Afsahi, A.M., MohsseniPour, M., Barzegary, A., Pirzapour, P., Mirghaderi, S.P., Salehi, M.A., Pashaei, Z., Nazeri, Z., Behnezhad, F., Ali, Z., Noori, T., Mehraeen, E., Sabatier, J.-M., Jahanfar, S., *Journal of Iranian Medical Council*, 5(1), 4-26 (2021). Doi : 10.18502/jimc.v5i1.9565

20-1 *Topology, antiviral functional residues and mechanism of IFITM1.*

Sun, F., Xia, Z., Han, Y., Minjun, G., Wang, L., Wu, Y., Sabatier, J.-M., Miao, L., Cao, Z., *Viruses*, 12 (3), 295-308 (2020).

20-2 *Antibacterial peptides.*

Sabatier, J.-M., *Antibiotics*, 9 (4), 142 (2020).

20-3 *Novel mutant phospholipase D from Hemiscorpius lepturus acts as a highly immunogen in BALB/c mice against the lethality of scorpion venom.*

Soleimani Moez, A., Sajedi, R., Pooshang-Bagheri, K., Sabatier, J.-M., Shahbazzadeh, D., *Molecules*, 25 (7), 1673-1692 (2020).

20-4 *SARS-CoV-2 & Covid-19: Key-roles of the renin-angiotensin system / Vitamin D impacting drug and vaccine developments.*

Cao, Z., Wu, Y., Faucon, E., Sabatier, J.M., *Infectious Disorders-Drug Targets*, 20, 348-349 (2020). Doi: 10.2174/1871526520999200505174704

20-5 Counter-regulatory 'renin-angiotensin' system-based candidate drugs to treat COVID-19 diseases in SARS-CoV-2-infected patients.

Annweiler, C., Cao, Z., Wu, Y., Faucon, E., Mouhat, S., Kovacic, H., Sabatier, J.M., *Infectious Disorders-Drug Targets*, 20, 407-408 (2020). Doi: 10.2174/1871526520666200518073329

20-6 Isolation, characterization and chemical synthesis of large spectrum antimicrobial cyclic dipeptide (L-leu-L-pro) from *Streptomyces misionensis* V16R3Y1 bacteria extracts. A novel ¹H-NMR metabolomic approach.

Saadouli, I., Zendah El Euch, I., Trabelsi, E., Mosbah, A., Redissi, A., Ferjani, R., Fhoula, I., Cherif, A., Sabatier, J.M., Sewald, N., Ouzari, H.I., *Antibiotics*, 9(5), 270-282 (2020).

20-7 Antimicrobials from venomous animals: an overview.

Yacoub, T., Rima, M., Karam, M., Sabatier, J.M., Fajloun, Z., *Molecules*, 25, 2402-2422 (2020).

20-8 A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis.

Karami, E., Sabatier, J.-M., Behdani, M., Irani, S., Kazemi-Lomedasht, F., *J. Enzyme Inhib. Med. Chem.*, 35(1), 1233-1239 (2020).

20-9 Neurological, cognitive and behavioral disorders during COVID-19: the nitric oxide track.

Annweiler, C., Bourgeois, A., Faucon, E., Cao, Z., Wu, Y., Sabatier, J.M., *Journal of American Geriatrics Society*, 10.1111/jgs.166671 (2020). Doi: 10.1111/jgs.166671

20-10 Point of view: Should COVID-19 patients be supplemented with vitamin D?

Annweiler, C., Cao, Z., Sabatier, J.M., *Maturitas*, 140, 24-26 (2020).

Doi: <https://doi.org/10.1016/j.maturitas.2020.06.003>

20-11 Point Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-7.

Gütschow, M., Eynde, J.J.V., Jampilek, J., Kang, C., Mangoni, A.A., Fossa, P., Karaman, R., Trabocchi, A., Scott, P.J.H., Reynisson, J., Rapposelli, S., Galdiero, S., Winum, J.Y., Brullo, C., Prokai-Tatrai, K., Sharma, A.K., Schapira, M., Azuma, Y.T., Cerchia, L., Spetea, M., Torri, G., Collina, S., Geronikaki, A., García-Sosa, A.T., Vasconcelos, M.H., Sousa, M.E., Kosalec, I., Tuccinardi, T., Duarte, I.F., Salvador, J.A.R., Bertinaria, M., Pellecchia, M., Amato, J., Rastelli, G., Gomes, P.A.C., Guedes, R.C., Sabatier, J.M., Estévez-Braun, A., Pagano, B., Mangani, S., Ragno, R., Kokotos, G., Brindisi, M., González, F.V., Borges, F., Miloso, M., Rautio, J., Muñoz-Torrero, D., *Molecules*, 25(13):2968 (2020). Doi: 10.3390/molecules25132968.

20-12 Montelukast drug may improve COVID-19 prognosis: a review of evidence.

Barré, J., Sabatier, J.M., Annweiler, C. *Frontiers in Pharmacology*, 11:1344 (2020). Doi: 10.3389/fphar.2020.01344.

20-13 Vitamin D and survival in COVID-19 patients. A quasi-experimental study.

Annweiler, C., Hanotte, B., de l'Éprevier, C.G., Sabatier, J.M., Lafaie, L., Célarier, T., *J. Steroid Biochem. Mol. Biol.* 204, 105771 (2020). Doi: 10.1016/j.jsbmb.2020.105771.

20-14 Potential inhibitory effect of *Apis mellifera*'s venom and of its two main components -Melittin and PLA2- on *Escherichia coli* F1F0-ATPase.

Nehme, H., Ayde, H., El Obeid, D., Sabatier, J.M., Fajloun, Z., *Antibiotics* 9(11):E824. (2020). Doi: 10.3390/antibiotics9110824.

20-15 Reinfection risk of novel coronavirus (COVID-19): a systematic review of current evidence.

SeyedAlinaghi, S.A., Oliaei, S., Kianzad, S., Alsahi, A.M., Mohssenipour, M., Barzegary, A., Mirzapour, P., Behnezhad, F., Noori, T., Mehraeen, E., Dadras, O., Voltarelli, F., Sabatier, J.M., *World J. Virol.* 9(5): 79-90 (2020). Doi: 10.5501/wjv.v9.i5.79.

19-1 Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-4.

Mangoni, AA., Guillou, C., Vanden Eynde, J.J., Hulme, C., Jampilek, J., Li, W., Prokai-Tatrai, K., Rautio, J., Collina, S., Tuccinardi, T., de Sousa, M.E., Sabatier, J.-M., Galdiero, S., Karaman, R., Kokotos, G., Torri, G., Luque, F.J., Vasconcelos, M.H., Hadjipavlou-Litina, D., Siciliano, C., Gütschow, M., Ragno, R., Gomez, P.A.C., Agrofoglio, L.A., Munoz-Torrero, D., *Molecules*, 24, 130-142 (2019).

19-2 Review: Therapeutic potential of carbonic anhydrase inhibitors.

Rahman, S., Bibi, S., Javed, T., Alam, F., Ali, A., Qureshi, Z.R., Ali, S., Ullah, M., Asad, M.H.B., Hasan, S.M.F., Sabatier, J.-M., Rizvanov, A.A., *Pak. J. Pharm. Sci.*, 32, 709-720 (2019).

19-3 Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-5.

Mangoni, AA., Vanden Eynde J.J., Jampilek, J., Hadjipavlou-Litina, D., Liu, H., Reynisson, J., de Sousa, M.E., Gomez, P.A.C., Prokai-Tatrai, K., Tuccinardi, T., Sabatier, J.-M., Luque, F.J., Rautio, J., Karaman, R., Vasconcelos, M.H., Gemma, S., Galdiero, S., Hulme, C., Collina, S., Gütschow, M., Kokotos, G., Siciliano, C., Capasso, R., Agrofoglio, L.A., Ragno, R., Munoz-Torrero, D., *Molecules*, 24, 2415-2428 (2019).

19-4 Proteomics study of southern Punjab Pakistani cobra (*Naja naja*: formerly *Naja naja karachiensis*) venom.

Bin Asad, M.H., McCleary, R., Salafutdinov, I., Alam, F., Shah, H.S., Bibi, S., Ali, A., Khalid, S., Hasan, S.M.F., Sabatier, J.-M., De Waard, M., Hussian, I., Rizvanov, A.A., *Toxicology & Environmental Chemistry*, 101, 91-116 (2019).

19-5 Venoms of Iranian Scorpions (*Arachnida*, *Scorpiones*) and their potential for drug discovery.

Kazemi, S.M., Sabatier, J.-M., *Molecules*, 24, 2670-2690 (2019).

19-6 Bee venom: overview of main compounds and bioactivities for therapeutic interests.

Wehbe, R., Frangieh, J., El Obeid, D., Sabatier, J.-M., Fajloun, Z., *Molecules*, 24, 2997-3009 (2019).

19-7 Development of a human scFv antibody targeting the lethal Iranian cobra (*Naja oxiana*) snake venom.

Kazemi-Lomedasht, F., Yamabhai, M., Sabatier, J.-M., Behdani, M., Reza, M., Shahbazzadeh, D., *Toxicon*, 171, 78-85 (2019).

19-8 Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-6.

Vanden Eynde, J.J., Mangoni, A.A., Rautio, J., Leprince, J., Azuma, Y.T., García-Sosa, A.T., Hulme, C., Jampilek, J., Karaman, R., Li, W., Gomes, P.A.C., Hadjipavlou-Litina, D., Capasso, R., Geronikaki,

A., Cerchia, .L, Sabatier, J.-M., Ragno, R., Tuccinardi, T., Trabocchi, A., Winum, J.Y., Luque, F.J., Prokai-Tatrai, K., Spetea, M., Gütschow, M., Kosalec, I., Guillou, C., Vasconcelos, M.H., Kokotos, G., Rastelli, G., de Sousa, M.E., Manera, C., Gemma, S., Mangani, S., Siciliano, C., . Galdiero, S., Liu, H., Scott, P.J.H., de Los Ríos, C., Agrofoglio, L.A., Collina, S., Guedes, R.C., Munoz-Torrero, D., *Molecules*, 25, 119-143 (2019).

18-1 Action mechanism of melittin-derived antimicrobial peptides, MDP1 and MDP2, de novo designed against multidrug-resistant bacteria.

Akbari, R., Hakemi-Vala, M., Hashemi, A., Aghazadeh, H., Sabatier, J.-M., Bagheri, K.P. *Amino acids*, 50, 1231-1243 (2018).

18-2 Lethal toxic dose (i.p. LD50), total protein contents and comparative hemolytic potential of (99mTc-labeled & non-labeled) Naja naja karachiensis venom.

Bin Asad, M.H., Asad, A.F., Bibi, S., Ullah, K., Javed, T., Ullah, M., Ali, A., Qureshi, Z.R., Amirzada, M.I., Al-Kahraman, Y.M., Hasan, S.M.F., Sabatier, J.-M., Rizvanov, A. *Pak. J. Pharm. Sci.*, 31, 685-689 (2018).

18-3 Membrane-active peptide PV3 efficiently eradicates multidrug-resistant Pseudomonas aeruginosa in a mouse model of burn infection.

Memariani, H., Shahbazzadeh, D., Sabatier, J.-M., Pooshang Bagheri, K. *APMIS*, 126, 114-122 (2018).

18-4 Vipers of the middle east: a rich source of bioactive molecules.

Rima, M., Alavi-Naini, S.M., Karam, M., Sadek, R., Sabatier, J.-M., Fajloun, Z. *Molecules*, 23, 2721-2737 (2018).

18-5 Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-3.

Mangoni, AA., Tuccinardi, T., Collina, S., Vanden Eynde, J.J., Munoz-Torrero, D., Karaman, R., Siciliano, C., de Sousa, M.E., Prokai-Tatrai, K., Rautio, J., Guillou, C., Gütschow, M., Galdiero, S., Liu, H., Agrofoglio, L.A., Sabatier, J.-M., Hulme, C., Kokotos, G., You, Q., Gomez, P.A.C. *Molecules*, 23, 1596-1606 (2018).

17-1 Breakthroughs in medicinal chemistry: New targets and mechanisms, new drugs, new hopes-2.

Munoz-Torrero, D., Mangoni, A.A., Liu, H., Hulme, C., Rautio, J., Karaman, R., de Sousa, M.E., Prokai-Tatrai, K., Sabatier, J.-M., Siciliano, C., Luque, F.J., Kokotos, G., Ranio, R., Collina, S., Guillou, C., Gütschow, M., Agrofoglio, L.A. *Molecules*, 23, 65-74 (2017).

17-2 Characteristics and lethality of a novel recombinant dermonecrotic venom phospholipase D from Hemiscorpius lepturus.

Torabi, E., Behdani, M., Chafi, M.H., Moazzami, R., Sabatier, J.-M., Khalaj, V., Shahbazzadeh, D., Bagheri, K.P. *Toxins*, 9, 102-118 (2017).

17-3 Treating autoimmune disorders with venom-derived peptides.

Shen, B., Cao, Z., Li, W., Sabatier, J.-M., Wu, Y. *Expert Opin. Biol. Ther.*, 17, 1065-1075 (2017).

17-4 Preface.

Sabatier, J.-M. *Infect. Disorders Drug Targets*, 17(1), 2 (2017).

17-5 **Special issue 'Structure-activity relationship of natural products'.**

Sabatier, J.-M. *Molecules*, 22(5) (2017).

17-6 **Consequences of *Androctonus mauretanicus* and *Buthus occitanus* scorpion venoms on electrolyte levels in rabbits.**

Daoudi, K., Chgoury, F., Rezzak, M., Bourouah, O., Boussadda, L., Soukri, A., Sabatier, J.-M., Oukkache, N. *Heliyon*, 3, 221-233 (2017).

17-7 **Peptide screen identifies a new NADPH oxidase inhibitor: impact on cell migration and invasion.**

Mousslim, M., Pagano, A., Andreotti, N., Garrouste, F., Thuault, S., Peyrot, V., Parat, F., Luis, J., Culcasi, M., Thétiot-Laurent, S., Pietri, S., Sabatier, J.-M., Kovacic, H., *Eur. J. Pharmacol.*, 794, 162-172 (2017).

16-1 **Genetic characterization of lactic acid bacteria from Tunisian milk waste and their antimicrobial activity against some bacteria implicated in nosocomial infections.**

Ghodhbane, H., Alessandria, V., Snoussi, M., Elleuch, L., Trabelsi, I., Abdelly, C., Sabatier, J.-M., Cocolin, L., Regaya, I. *Infect. Disord. Drug Targets*, 16, 182-191 (2016).

16-2 **Mechanism of action and in vitro activity of short hybrid antimicrobial peptide PV3 against *Pseudomonas aeruginosa*.**

Memariani, H., Shahbazzadeh, D., Sabatier, J.-M., Memariani, M., Karbalaimahdi, A., Bagheri, K.P., *Biochem. Biophys. Res. Commun.*, 479, 103-108 (2016).

16-3 **Editorial.**

Sabatier, J.-M. *Infect. Disorders Drug Targets*, 16(2), 78 (2016).

15-1 **Comparison of the neurotoxic and myotoxic effects of two Moroccan scorpion venoms and their neutralization by experimental polyclonal antivenom.**

Oukkache, N., Ahmad Rusmili, M.R., Othman, I., Ghalim, N., Chgoury, F., Boussadda, L., El Mdaghri, N., Sabatier, J.-M., *Life Sciences*, 124, 1-7 (2015).

15-2 **Correspondences between the binding characteristics of a non-natural peptide, *Lei-Dab7*, and the distribution of SK subunits in the rat central nervous system.**

Aidi-Knani, S., Pezard, L., Mpari, B., Ben Hamida, J., Sabatier, J.-M., Mourre, C., Regaya, I., *Eur. J. Pharmacol.*, 752, 106-111 (2015).

15-3 **Endogenous animal toxin-like human beta-defensin 2 inhibits own K⁺ channels through interaction with channel extracellular pore region.**

Yang, W., Feng, J., Xiang, F., Xie, Z., Zhang, G., Sabatier, J.-M., Cao, Z., Li, W., Chen, Z., Wu, Y., *Cell. Mol. Life Sci.*, 72, 845-853 (2015).

15-4 **Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight tumor invasion.**

Dardevet, L., Rani, D., Aziz, T., Bazin, I., Sabatier, J.-M., Fadl, M., Brambilla, E., De Waard, M., *Toxins*, 7, 1079-1101 (2015).

15-5 ***Small-conductance Ca²⁺-activated potassium type 2 channels regulate the formation of contextual fear memory.***

Murthy, S.R., Sherrin, T., Jansen, C., Nijholt, I., Robles, M., Dolga, A.M., Andreotti, N., Sabatier, J.-M., Knaus, H.G., Penner, R., Todorovic, C., Blank, T., *PLoS One*, 10, e0127264 (2015).

15-6 ***Characterization of Am IT, an anti-insect β -toxin isolated from the venom of scorpion *Androctonus mauretanicus*.***

Oukkache, N., El Jaoudi, R., Chgoury, F., Rocha, M.T., Sabatier, J.-M., *Acta Physiologica Sinica*, 67, 295-304 (2015).

15-7 ***Bacteriocins active against multi-resistant Gram-negative bacteria implicated in nosocomial infections.***

Ghodhbane, H., Elaidi, S., Sabatier, J.-M., Achour, S., Benhamida, J., Regaya, I., *Infect. Disord. Drug Targets*, 15, 2-12 (2015).

14-1 ***Unusual binding mode of scorpion toxin BmKTX onto potassium channels relies on its distribution of acidic residues.***

Chen, Z., Hu, Y., Hu, J., Yang, W., Sabatier, J.-M., De Waard, M., Cao, Z., Li, X., Han, S., Wu, Y., *Biochem. Biophys. Res. Comm.*, 447, 70-76 (2014).

14-2 ***Protein content analysis and antimicrobial activity of the crude venom of *Montivipera Bornmuelleri*, a viper from Lebanon.***

Accary, C., Hraoui-Bloquet, S., Hamze, M., Mallem, Y., El Omar, F., Sabatier, J.-M., Desfontis, J.C., Fajloun, Z., *Infect. Disord. Drug Targets*, 14, 49-55 (2014).

14-3 ***Evaluation of the lethal potency of scorpion and snake venoms and comparison between intraperitoneal and intravenous injection routes.***

Oukkache, N., El Jaoudi, R., Ghalim, N., Chgoury, F., Bouhaouala, B., El Mdaghri, N., Sabatier, J.-M., *Toxins*, 6, 1873-1881 (2014).

13-1 ***Peptide binding to Ochratoxin A mycotoxin: a new approach in conception of biosensors.***

Bazin, I., Andreotti, N., Hassine, A.I., De Waard, M., Sabatier, J.-M., Gonzalez, C., *Biosensors Bioelectronics*, 40, 240-246 (2013).

13-2 ***SKCa channels blockage increases the expression of Adenosine A2A receptor in Jurkat human T cells.***

Regaya, I., Aidi-Knani, S., By, Y., Condo, C., Gerolami, V., Berge-Lefranc, J.-L., Ben Hamide, J., Sabatier, J.-M., Fenouillet, E., Guieu, R., Ruf, J., *Bioresearch Open Access*, 2, 163-168 (2013).

13-3 ***Cell penetration properties of a highly efficient mini Maurocalcine peptide.***

Tisseyre, C., Bahembera, E., Dardevet, L., Sabatier, J.-M., Ronjat, M., De Waard, M., *Pharmaceuticals*, 6, 320-339 (2013).

13-4 ***Two conserved arginine residues from the SK3 channel outer vestibule control selectivity of recognition by scorpion toxins.***

Feng, J., Hu, Y., Yi, H., Yin, S., Han, S., Hu, J., Chen, Z., Yang, W., Cao, Z., De Waard, M., Sabatier, J.-M., Li, W., Wu, Y., *J. Biol. Chem*, 288, 12544-12553 (2013).

13-5 *The deciphered genome of Mesobuthus martensii uncovers the resistance mysteries of scorpion to its own venom and toxins at the ion channel level.*

Andreotti, N., Sabatier, J.-M., *Toxins*, 5, 2209-2211 (2013).

12-1 *Lacticin LC14, a new bacteriocin produced by Lactococcus lactis BMG6.14: isolation, purification and partial characterization.*

Lasta, S., Ouzari, H., Andreotti, N., Fajloun, Z., Mansuelle, P., Boudabous, A., Sampieri, F., Sabatier, J.-M., *Infect. Disord. Drug Targets*, 12, 316-325 (2012).

12-2 *Small efficient cell-penetrating peptides derived from scorpion toxin maurocalcine.*

Poillot, C., Bichraoui, H., Tisseyre, C., Bahembera, E., Andreotti, N., Sabatier, J.-M., Ronjat, M., De Waard, M., *J. Biol. Chem.*, 287, 17331-17342 (2012).

12-3 *Strategies toward structural and functional 'optimization' of animal peptide toxins.*

Andreotti, N., Ziadi, H., Mouhat, S., De Waard, M., Sabatier, J.-M., *Int. J. Med. Biomed. Res.*, 1, 91-96 (2012).

12-4 *Selective positive modulator of calcium-activated potassium channels exerts beneficial effects in a mouse model of spinocerebellar ataxia type 2.*

Kasamu, A.W., Hougaard, C., Rode, F., Jacobsen, T.A., Sabatier, J.-M., Eriksen, B.L., Strobaek, D., Liang, X., Egorova, P., Vorontsova, D., Christophersen, P., Ronn, L.C., Bezprozvanny, *Chemistry & Biology*, 19, 1340-1353 (2012).

11-1 *Animal venoms: from deadly arsenals (toxins) to therapeutic drug candidates.*

Sabatier, J.-M., *Inflamm. Allergy Drug Targets*, 10, 312 (2011). Introduction to a special issue.

11-2 *Analysis of the interacting surface of maurotoxin with the voltage-gated Shaker B K⁺ channel.*

Fajloun, Z., Andreotti, N., Fathallah, M., Sabatier, J.-M., De Waard, M., *J. of Pept. Sci.*, 17, 200-210 (2011).

10-1 *SP receptor blockade decreases stretch-induced lung cytokines and lung injury.*

Brégeon, F., Steinberg, J.-G., Andreotti, N., Sabatier, J.-M., Delpierre, S., Ravailhe, S., Jammes, Y., *J. Physiol.*, 588, 1309-1319 (2010).

10-2 *Protein-protein recognition control by modulating electrostatic interactions.*

Han, S., Yin, S., Shijin, Y., Mouhat, S., Qiu, S., Cao, Z., Sabatier, J.-M., Wu, Y., Li, W., *J. of Proteome Res.*, 9, 3118-3125 (2010).

10-3 *Therapeutic value of peptides from animal venoms.*

Andreotti, N., Jouirou, B., Mouhat, S., Mouhat, L., Sabatier, J.-M., *Amino Acids, Peptides and Proteins, Comprehensive Natural Products II Chemistry and Biology*, Mander L. & Lui H.D. Eds., Elsevier: Oxford, vol. 5, pp 287-303, 2010.

10-4 *Structure-function relationships of KTS Disintegrins and design of antiangiogenic drugs.*

Kallech-Ziri, O., Luis, J., Fajloun, Z., Sabatier, J.-M., Lehmann, M., El Ayeb, M., Marrakchi, N., Loret, E., *Letters in Drug Design & Discovery*, 7, 36-40 (2010).

09-1 Small-conductance Ca²⁺-activated potassium type 2 channels regulate the formation of contextual fear memory.

Nijholt, I., Van den Akker, H., Kye, M.-J., Sabatier, J.-M., Knaus, H., Spiess, J., Blank, T., *J. of Neurosci.*, in press (2009).

09-2 Drug targets in viral infections.

Sabatier, J.-M., *Infect. Disord. Drug Targets*, 9, 100 (2009). Introduction to a special issue.

08-1 Chemical synthesis and 1H-NMR 3D structure determination of AgTx2-MTX chimera, a new potential blocker for Kv1.2 channel, derived from MTX and AgTx2 scorpion toxins.

Pimentel, C., M'Barek, S., Visan, V., Grissmer, S., Sampieri, F., Sabatier, J.-M., Darbon, H., Fajloun, Z., *Protein Science*, 17, 107-118 (2008).

08-2 Animal toxins acting on voltage-gated potassium channels.

Mouhat, S., Andreotti, N., Jouirou, B., Sabatier, J.-M., *Current Pharmaceutical Design*, 14, 2503-2518 (2008).

08-3 Effect of Cu²⁺ on the oxidative folding of synthetic Maurotoxin in vitro.

Regaya, I., Andreotti, N., Di Luccio, E., De Waard, M., Sabatier, J.-M., *J. Biomolecular Structure and Dynamics*, 26, 75-82 (2008).

08-4 Chemical synthesis and characterization of J46 peptide, an atypical class IIa bacteriocin from *Lactococcus lactis* subsp. *Cremonis* J46 strain.

Lasta, S., Fajloun, Z., Darbon, H., Mansuelle, P., Andreotti, N., Sabatier, J.-M., Boudabous, A., Sampieri, F., *The Journal of Antibiotics*, 61, 89-93 (2008).

08-5 Design of a disulfide-less, pharmacologically-inert and chemically-competent analog of Maurocalcine for the efficient transport of impermeant compounds into cells.

Ram, N., Weiss, N., Texier-Nogues, I., Aroui, S., Andreotti, N., Pirollet, F., Ronjat, M., Sabatier, J.-M., Darbon, H., Jacquemont, V., De Waard, M., *J. Biol. Chem.*, 283, 27048-27056 (2008).

07-1 Modulators of small and intermediate conductance calcium-activated potassium channels and their therapeutic indications.

Wulff, H., Kolski-Andreaco, A., Sankaranayanan, A., Sabatier, J.-M., Shakkottai, V., *Current Medicinal Chemistry*, 14, 1437-1457 (2007).

06-1 Pharmacological profiling of OSK1 analogues with a trimmed N-terminal domain.

Mouhat, S., Teodorescu, G., Homerick, D., Visan, V., Wulff, H., Wu, Y.L., Grissmer, S., Darbon, H., De Waard, M., Sabatier, J.-M., *Mol. Pharmacology*, 69, 354-362 (2006).

06-2 Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor.

Boisseau, S., Mabrouk, K., Narendra, R., Garmy, N., Collin, V., Tadmouri, A., Mikati, M., Sabatier, J.-M., Ronjat, M., Fantini, J., De Waard, M., *Biochem. Biophys. Acta*, 1758, 308-319 (2006).

06-3 CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity.

Guieu, R., Fenouillet, E., Devaux, C., Fajloun, Z., Carrega, L., Sabatier, J.-M., Sauze, N., Marguet, D., *Behav. Brain Res.*, 166, 230-235 (2006).

06-4 Transient loss of voltage control of Ca²⁺ release in the presence of maurocalcine in skeletal muscle.

Pouvreau, S., Csernoch, L., Allard, B., Sabatier, J.-M., De Waard, M., Ronjat, M., Jacquemont, V., *Biophys. J.*, 91, 2206-2215 (2006).

06-5 Resistance of Hepatitis C virus to NS3-4A protease inhibitors: molecular mechanism of drug resistance induced by R155Q, A156T, D168A and D168V mutations.

Courcambeck J., Bouzidi, M., Perbost, R., Jouirou, B., Amrani, N., Cacoub, P., Pèpe, J., Sabatier, J.-M., Halfon, P., *Antiviral Therapy*, 11, 847-855 (2006).

06-6 Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy.

Beraud-Juven, E., Viola, A., Regaya, I., Confort-Gouny, S., Siaud, P., Ibarrola, D., Le Fur, Y., Barbaria, J., Pélissier, J.-F., Medina, I., Sabatier, J.-M., Cozzone, P., *Annals of Neurology*, 60, 586-596 (2006).

05-1 K⁺ channel types targeted by synthetic OSK1, a toxin from *Orthochirus scrobiculosus* scorpion venom.

Mouhat, S., Visan, V., Ananthakrishnan, S., Wulff, H., Grissmer, S., Darbon, H., De Waard, M., Sabatier, J.-M., *Biochem. J.*, 385, 95-104 (2005).

05-2 Contribution of the functional dyad of animal toxins acting on voltage-gated Kv1-type channels.

Mouhat, S., De Waard, M., Sabatier, J.-M., *J. Peptide Sci.*, 11, 65-68 (2005).

05-3 Maurocalcine and domain A of the II-III loop of the dihydropyridine receptor Ca_v1.1 subunit share common binding sites on the skeletal ryanodine receptor.

Altafaj, X., Cheng, W., Estève, E., Urbani, J., Grunwald, D., Sabatier, J.-M., Coronado, R., De Waard, M., Ronjat, M., *J. Biol. Chem.*, 280, 4013-4016 (2005).

05-4 Transduction of the scorpion toxin maurocalcine into cells. Evidence that the toxin crosses the plasma membrane.

Estève, E., Mabrouk, K., Dupuis, A., Smida-Rezgui, S., Altafaj, X., Grunwald, D., Platel, J.-C., Andreotti, N., Marty, I., M., Sabatier, J.-M., Ronjat, M., De Waard, M., *J. Biol. Chem.*, 280, 12833-12839 (2005).

05-5 Molecular modeling and docking simulations of scorpion toxins and related analogues on human SKCa2 and SKCa3 channels.

Andreotti, N., Di Luccio, E., Sampieri, F., De Waard, M., Sabatier, J.-M., *Peptides*, 26, 1095-1108 (2005).
Article ranked first in the « *Top 25 Hottest Articles* » of *Peptides*.

05-6 Acting on the number of molecular contacts between Maurotoxin and Kv1.2 channel impacts ligand affinity.

M'Barek, S., Chagot, B., Andreotti, N., Visan, V., Mansuelle, P., Grissmer, S., Marrakchi, M., El Ayeb, M., Sampieri, F., Darbon, H., Fajloun, Z., De Waard, M., Sabatier, J.-M., *Proteins*, 60, 401-411 (2005).

05-7 Differential effects of maurocalcine on Ca²⁺ release events and depolarisation-induced Ca²⁺ release in rat skeletal muscle.

Szappanos, H., Smida-Rezgui, S., Cseri, J., Simut, C., Sabatier, J.-M., De Waard, M., Kovacs, L., Csernoch, L., Ronjat, M., *J. Physiol.*, 565, 843-853 (2005).

05-8 Blockade of NMDA receptors enhances spontaneous sharp waves in rat hippocampal slices.

Colgin, L., Jia, Y., Sabatier, J.-M., Lynch, G., *Neuroscience Letters*, 385, 46-51 (2005).

05-9 Lebestatin, a short disintegrin from *Macrovipera lebetina* venom, inhibits integrin-mediated adhesion, migration of tumor cells and in vivo angiogenesis.

Kallech-Ziri, O., Luis, J., Daoud, S., Srairi, N., Andreotti, N., Lehmann, M., Zouari, R., Bazaa, A., Marvaldi, J., Sabatier, J.-M., El Ayeb, M., Marrakchi, N., *Lab. Invest.*, 1-10 (2005).

05-10 The impact of the fourth disulfide bridge in scorpion toxins of the α -KTx6 sub-family.

Carrega, L., Mosbah, A., Ferrat, G., Beeton, C., Andreotti, N., Mansuelle, P., Darbon, H., De Waard, M., Sabatier, J.-M., *Proteins*, 61, 1010-1023 (2005).

04-1 The « functional » dyad of scorpion toxin Pi1 is not by itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels.

Mouhat, S., Mosbah, A., Visan, V., Wulff, H., Delepierre, M., Darbon, H., Grissmer, S., De Waard, M., Sabatier, J.-M., *Biochem. J.*, 377, 25-36 (2004).

04-2 Cobatoxin 1 from *Centruroides noxius* scorpion venom: Chemical synthesis, 3-D structure in solution, pharmacology and docking on K⁺ channels.

Jouirou, B., Mosbah, A., Visan, V., Grissmer, S., M'Barek, S., Fajloun, Z., Van Rietschoten, J., Devaux, C., Rochat, H., Lippens, G., El Ayeb, M., De Waard, M., Mabrouk, K., Sabatier, J.-M., *Biochem. J.*, 377, 37-49 (2004).

04-3 Diversity of folds in animal toxins acting on ion channels.

Mouhat, S., Jouirou, B., Mosbah, A., De Waard, M., Sabatier, J.-M., *Biochem. J.*, 378, 717-726 (2004) ; Impact factor = 29.4.

04-4 Toxin determinants required for interaction with voltage-gated K⁺ channels.

Jouirou, B., Mouhat, S., Andreotti, N., De Waard, M., Sabatier, J.-M., *Toxicon*, 43, 909-914 (2004).

04-5 Block of maurotoxin and charybdotoxin on human intermediate-conductance calcium-activated potassium channels (hKCa1).

Visan, V., Sabatier, J.-M., Grissmer, S., *Toxicon*, 43, 973-980 (2004).

04-6 First chemical synthesis of a scorpion α -toxin affecting sodium channels : the AaH I toxin of *Androctonus australis Hector*.

M'Barek, S., Fajloun, Z., Cestèle, S., Devaux, C., Mansuelle, P., Mosbah, A., Jouirou, B., Mantegazza, M., Van Rietschoten, J., El Ayeb, M., Rochat, H., Sabatier, J.-M., Sampieri, F., *J. Peptide Sci.*, 10, 666-677 (2004).

04-7 Small conductance calcium-activated K⁺ channels, SKCa, but not voltage-gated K⁺ (Kv) channels, are implicated in the antinociception induced by CGS21680, a A2A adenosine receptor agonist.

Regaya, I., Pham, T., Andreotti, N., Sauze, N., Carrega, L., Martin-Eauclaire, M.-F., Jouirou, B., Peragut, J.-C., Vacher, H., Rochat, H., Devaux, C., Sabatier, J.-M., Guieu, R., *Life Sciences*, 76, 367-377 (2004).

04-8 Mapping of maurotoxin (MTX) binding sites on hKv1.2, hKv1.3 and hKCa1 channels.

Visan, V., Fajloun, Z., Sabatier, J.-M., Grissmer, S., *Mol. Pharmacology*, 66, 1103-1112 (2004).

04-9 Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins.

Regaya, I., Beeton, C., Ferrat, G., Andreotti, N., Darbon, H., De Waard, M., Sabatier, J.-M., *J. Biol. Chem.*, 279, 55690-55696 (2004).

03-1 Maurotoxin, a potent inhibitor of intermediate conductance Ca²⁺-activated potassium channels.

Castle, N.A., London, D.B., Creech, C., Fajloun, Z., Stocker, J., Sabatier, J.-M., *Mol. Pharmacology*, 63, 409-418 (2003).

03-2 Maurocalcine and peptide A stabilize distinct subconductance states of ryanodine receptor type 1 (RyR1) revealing a proportional gating mechanism.

Chen, L., Estève, E., Sabatier, J.-M., Ronjat, M., De Waard, M., Allen, P.D., Pessah, I.N., *J. Biol. Chem.*, 278, 16095-16106 (2003).

03-3 Solution structure of Pi4, a short four-disulfide-bridged scorpion toxin specific of potassium channels.

Guijarro, J.I., M'Barek, S., Gomez-Lagunas, F., Garnier, D., Rochat, H., Sabatier, J.-M., Possani, L.D., Delepierre, M., *Protein Science*, 12, 1844-1854 (2003).

03-4 A maurotoxin with constrained standard disulfide bridging – Innovative strategy of chemical synthesis, pharmacology and docking on K⁺ channels.

M'Barek, S., Lopez-Gonzalez, I., Andreotti, N., di Luccio, E., Visan, V., Grissmer, S., Judge, S., El Ayeb, M., Darbon, H., Rochat, H., Sampieri, F., Béraud, E., Fajloun, Z., De Waard, M., Sabatier, J.-M., *J. Biol. Chem.*, 278, 31095-31104 (2003).

03-5 Synthesis and characterization of Pi4, a scorpion toxin from *Pandinus imperator* that acts on K⁺ channels.

M'Barek, S., Mosbah, A., Sandoz, G., Mansuelle, P., Fajloun, Z., Rochat, H., Sampieri, H., Olamendi-Portugal, T., Possani, L., Delepierre, M., De Waard, M., Sabatier, J.-M., *Eur. J. Biochem.*, 270, 3583-3592 (2003).

03-6 Critical amino acid residues determine the binding affinity and the Ca²⁺ release efficacy of maurocalcine in skeletal muscle cells.

Estève, E., Smida-Rezgui, S., Sarkozi, S., Regaya, I., Chen, L., Altafaj, X., Rochat, H., Allen, P., Pessah, I., Marty, I., Sabatier, J.-M., Jona, I., De Waard, M., Ronjat, M., *J. Biol. Chem.*, 278, 37822-37831 (2003).

02-1 Evolution of Maurotoxin conformation and blocking efficacy towards Shaker B channels during the course of folding and oxidation in vitro.

Di Luccio, E., Matavel, A., Opi, S., Regaya, I., Sandoz, G., M'Barek, S., Carlier, E., Estève, E., Carrega, L., Fajloun, Z., Rochat, H., Loret, E., De Waard, M., Sabatier, J.-M., *Biochem. J.*, 361, 409-416 (2002).

02-2 Liposomal encapsulation enhances SPC3 antiviral efficacy against human immunodeficiency virus type 1 infection in human lymphocytes.

De Mareuil, J., Mabrouk, K., Doria, E., Moulard, M., De Chasteigner, S., Oughideni, R., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *Antiviral Res.*, 54, 175-188 (2002).

02-3 The interaction between the I-II loop and the III-IV loop of Cav2.1 contributes to voltage-dependent inactivation in a beta-dependent manner.

Geib, S., Sandoz, G., Cornet, V., Mabrouk, K., Fund-Saunier, O., Bichet, D., Villaz, M., Hoshi, T., Sabatier, J.-M., De Waard, M., *J. Biol. Chem.*, 277, 10003-10013 (2002).

02-4 Synthesis, 3-D structure and pharmacology of a reticulated chimera derived from maurotoxin and Tsk scorpion toxins.

Fajloun, Z., Ferrat, G., Carlier, E., M'Barek, S., Regaya, I., Fathallah, M., Rochat, H., Darbon, H., De Waard, M., Sabatier, J.-M., *Biochem. Biophys. Res. Comm.*, 291, 640-648 (2002).

02-5 Modeling of the III-IV loop, a domain involved in calcium channel Cav2.1 inactivation, highlights a structural homology with the gamma subunit of G proteins.

Fathallah, M., Sandoz, G., Mabrouk, K., Geib, S., Urbani, J., Villaz, M., Ronjat, M., Sabatier, J.-M., De Waard, M., *Eur. J. Neuroscience*, 16, 219-228 (2002).

01-1 Kaliotoxin, a voltage-gated potassium channel blocker, inhibits encephalitogenic T cell activation.

Beeton, C., Barbaria, J., Benoliel, A.-M., Giraud, P., Gola, M., Sabatier, J.-M., Bernard, D., Crest, C., Béraud, E., *J. Immunol.*, 166, 936-944 (2001).

01-2 Disulfide bridge reorganization induced by proline mutations in Maurotoxin.

Carlier, E., Fajloun, Z., Mansuelle, P., Fathallah, M., Mosbah, A., Oughideni, R., di Luccio, E., Sandoz, G., Geib, S., Regaya, I., Rochat, H., Darbon, H., Sabatier, J.-M., De Waard, M., *FEBS Lett.*, 489, 202-207 (2001).

01-3 Parameters affecting oxidation/folding of Maurotoxin, a four disulfide-bridged scorpion toxin.

Di Luccio, E., Azulay, D.O., Regaya, I., Fajloun, Z., Sandoz, G., Mansuelle, P., Kharrat, R., Fathallah, M., Carrega, L., Estève, E., Rochat, H., De Waard, M., Sabatier, J.-M., *Biochem. J.*, 358, 681-692 (2001).

01-4 **Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K⁺ channel, SKCa₂.**

Shakkottai, V., Regaya, I., Wulff, H., Fajloun, Z., Fathallah, M., Tomita, H., Gargus, J.J., Cahalan, M., Sabatier, J.-M., Chandy, K.G., *J. Biol. Chem.*, 276, 43145-43151 (2001).

01-5 **Chemical synthesis, molecular modeling and anti-microbial activity of a novel bacteriocin, MMFII.**

Ferchichi, M., Fathallah, M., Mansuelle, P., Rochat, H., Sabatier, J.-M., Manai, M., Mabrouk, K. *Biochem. Biophys. Res. Comm.*, 289(1), 13-18 (2001).

00-1 **Chemical synthesis and characterization of Maurocalcine, a scorpion toxin that activates Ca²⁺ release channel/ryanodine receptors.**

Fajloun, Z., Kharrat, R., Chen, L., Lecomte, C., di Luccio, C., Bichet, D., El Ayeb, M., Rochat, H., Allen, P.D., Pessah, I.N., De Waard, M., Sabatier, J.-M., *FEBS Lett.*, 469, 179-185 (2000).

00-2 **Maurotoxin and Kv1.1 channel: Voltage-dependent binding upon enantiomerization of the scorpion toxin disulfide bridge Cys 31-Cys 34.**

Lecomte, C., Ben Khalifa, R., Martin-Eauclaire, M.-F., Kharrat, R., El Ayeb, M., Darbon, H., Rochat, H., Crest, M., Sabatier, J.-M., *J. Peptide Res.*, 55, 246-254 (2000).

00-3 **A new fold in the scorpion toxin family, associated with an activity on a ryanodine-sensitive calcium channel.**

Mosbah, A., Kharrat, R., Fajloun, Z., Renisio, G., Blanc, E., Sabatier, J.-M., El Ayeb, M., Darbon, H., *Proteins*, 40, 436-442 (2000).

00-4 **Synthesis, ¹H-NMR structure and activity of a three disulfide-bridged Maurotoxin analog designed to restore the consensus motif of scorpion toxins.**

Fajloun, Z., Ferrat, G., Carlier, C., Fathallah, M., Lecomte, C., Sandoz, G., di Luccio, E., Mabrouk, K., Legros, C., Darbon, H., Rochat, H., Sabatier, J.-M., De Waard, M., *J. Biol. Chem.*, 275, 13605-13612 (2000).

00-5 **Maurotoxin, a four disulfide-bridged toxin from the chactoid scorpion *Scorpio maurus*, blocks voltage-gated K⁺ channels.**

Carlier, E., Avdonin, V., Geib, S., Kharrat, R., Rochat, H., Sabatier, J.-M., Hoshi, T., De Waard, M., *J. Peptide Res.*, 55, 419-427 (2000).

00-6 **Biophysical and molecular mechanisms of the action of Maurotoxin on Shaker potassium channels.**

Avdonin, V., Nolan, B., Sabatier, J.-M., De Waard, M., Hoshi, T., *Biophys. J.*, 79, 776-787 (2000).

00-7 **Chemical synthesis and characterization of Pi1, a scorpion toxin from *Pandinus imperator* active on K⁺ channels.**

Fajloun, Z., Carlier, E., Lecomte, C., Geib, S., di Luccio, E., Bichet, D., Mabrouk, K., Rochat, H., De Waard, M., Sabatier, J.-M., *Eur. J. Biochem.*, 267, 5149-5155 (2000).

00-8 **Reversibility of the Ca²⁺ channel alpha1-beta subunit interaction.**

Bichet, D., Lecomte, C., Sabatier, J.-M., Felix, R., De Waard, M., *Biochem. Biophys. Res. Com.*, 277, 729-735 (2000).

00-9 **Maurotoxin vs Pi1/HsTx1: Towards new insights in the understanding of their distinct disulfide bridge patterns.**

Fajloun, Z., Mosbah, A., Carlier, E., Mansuelle, P., Fathallah, M., Sandoz, G., di Luccio, E., Devaux, C., Rochat, H., Darbon, H., De Waard, M., Sabatier, J.-M., *J. Biol. Chem.*, 275, 39394-39402 (2000).

00-10 Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop.

Carlier, C., Mabrouk, K., Moulard, M., Rochat, H., De Waard, M., Sabatier, J.-M., *J. Peptide Res.*, 56, 427-437 (2000).

99-1 Chemical synthesis and structure-activity of TsK, a novel scorpion toxin acting on apamin-sensitive SK channel.

Lecomte, C., Ferrat, G., Fajloun, Z., Van Rietschoten, J., Rochat, H., Martin-Eauclaire, M.-F., Darbon, H., Sabatier, J.-M., *J. Peptide Res.*, 54, 369-376 (1999).

99-2 V3 loop-derived peptide SPC3 inhibits infection of CD4-negative and Galactosylceramide-negative cells by LAV-2/B.

Moulard, M., Mabrouk, K., Martin, I., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *J. Peptide Res.*, 53, 647-655 (1999).

99-3 Three-dimensional structure of scorpion toxins: Towards a new model of interaction with potassium channels.

Darbon, H., Blanc, E., Sabatier, J.-M., *Perspectives in Drug Discovery and Design*, H. Darbon & J.-M. Sabatier Eds., KLUWER/ESCOM, Kluwer Academic Publishers 15/16, 40-60 (1999).

98-1 An anti-HIV peptide construct derived from the cleavage region of the Env precursor acts on Env fusogenicity through the presence of a functional cleavage sequence.

Barbouche, R., Sabatier, J.-M., Fenouillet, E., *Virology*, 247, 137-143 (1998).

98-2 Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.

Barbouche, R., Fenouillet, E., Papandréou, M.-J., Kiény, M.-P., Sabatier, J.-M., *J. Peptide Res.*, 52, 283-288 (1998).

98-3 Synthetic peptides as tools to investigate the structure and pharmacology of potassium channel-acting short-chain scorpion toxins.

Lecomte, C., Sabatier, J.-M., Van Rietschoten, J., Rochat, H., *Biochimie*, 80, 151-154 (1998).

98-4 Maurotoxin, a four disulfide bridges scorpion toxin acting on K⁺ channels.

Rochat, H., Kharrat, R., Sabatier, J.-M., Mansuelle, P., Crest, M., Martin-Eauclaire, M.-F., Sampieri, F., Oughideni, R., Mabrouk, K., Jacquet, G., Van Rietschoten, J., El Ayeb, M., *Toxicon*, 36, 1609-1611 (1998).

98-5 SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells.

Barbouche, R., Miquelis, R., Sabatier, J.-M., Fenouillet, E., *J. Peptide Science*, 4, 479-485 (1998).

97-1 In vivo protection against *Androctonus australis* Hector scorpion toxin and venom by immunization with a synthetic analog of toxin II.

Zenouaki, I., Kharrat, R., Sabatier, J.-M., Devaux, C., Karaoui, H., Van Rietschoten, J., El Ayeb, M., Rochat, H., *Vaccine*, 15, 187-194 (1997).

97-2 Monoclonal antibodies neutralizing the toxin II from *Androctonus australis* Hector scorpion venom: usefulness of a synthetic, non-toxic analog.

Devaux, C., Clot-Faybesse, O., Juin, M., Mabrouk, K., Sabatier, J.-M., Rochat, H., *FEBS*, 412, 456-460 (1997).

97-3 Differential involvement of disulfide bridges on the folding of a scorpion toxin.

Calabro, V., Sabatier, J.-M., Blanc, E., Lecomte, C., Van Rietschoten, J., Darbon, H., *J. Peptide Res.*, 50, 39-47 (1997).

97-4 Solution structure of Maurotoxin, a scorpion toxin from *Scorpio maurus*, with high affinity for voltage-gated potassium channels.

Blanc, E., Sabatier, J.-M., Kharrat, R., Meunier, S., El Ayeb, M., Van Rietschoten, J., Darbon, H., *Proteins*, 29, 321-333 (1997).

97-5 Solution structure of TsKapa, a charybdotoxin-like scorpion toxin from *Tityus serrulatus* with high affinity for apamin-sensitive Ca^{2+} -activated K^+ channels.

Blanc, E., Lecomte, C., Van Rietschoten, J., Sabatier, J.-M., Darbon, H., *Proteins*, 29, 359-369 (1997).

96-1 V3 loop-derived multibranched peptides as inhibitors of HIV infection in $CD4^+$ and $CD4^-$ cells.

Fantini, J., Yahi, N., Mabrouk, K., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *Perspectives in Drug Discovery and Design*, J. Fantini & J.-M. Sabatier Eds., Escom Science Publishers, 5, 243-250 (1996).

96-2 Chemical synthesis and characterization of Maurotoxin, a short scorpion toxin with four disulfide bridges acting on K^+ channels.

Kharrat, R., Mabrouk, K., Crest, M., Darbon, H., Oughideni, R., Martin-Eauclaire, M.-F., Jacquet, G., El Ayeb, M., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *Eur. J. Biochem.*, 242, 491-498 (1996).

96-3 Synthesis and characterization of Leiurotoxin I analogs lacking one disulfide bridge: Evidence that disulfide pairing 3-21 is not required for full toxin activity.

Sabatier, J.-M., Lecomte, C., Mabrouk, K., Darbon, H., Oughideni, R., Canarelli, S., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., *Biochemistry*, 35, 10641-10647 (1996).

96-4 Anti-HIV activity of multibranched peptide constructs derived either from the cleavage sequence or from the transmembrane domain (gp41) of the human immunodeficiency virus type 1 envelope.

Sabatier, J.-M., Mabrouk, K., Moulard, M., Rochat, H., Van Rietschoten, J., Fenouillet, E., *Virology*, 223, 406-408 (1996).

95-1 Structure-activity relationship study of a scorpion toxin with high affinity for apamin-sensitive potassium channels by means of the solution structure of analogues.

Inisan, A.G., Meunier, S., Fedelli, O., Altbach, M., Fremont, V., Sabatier, J.-M., Thévan, A., Cambillau, C., Darbon, H., *Int. J. Peptide Protein Res.*, 45, 441-450 (1995).

95-2 Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of HIV-1 gp120 bind to galactosylceramide and block HIV-1 infection in a human $CD4$ -negative mucosal epithelial cell line.

Yahi, N., Sabatier, J.-M., Baghdiguian, S., Gonzalez-Scarano, F., Fantini, J., *J. Virol.*, 69, 320-325 (1995).

95-3 SPC3, a nontoxic peptide inhibitor of HIV infection.

Sabatier, J.-M., Baghdiguian, S., Yahi, N., Rochat, H., Van Rietschoten, J., Fantini, J., *In Vitro*, 31, 415-418 (1995).

95-4 SPC3, a synthetic peptide derived from the V3 domain of HIV-1 gp120, inhibits HIV-1 entry into $CD4^+$ and $CD4^-$ cells by two distinct mechanisms.

Yahi, N., Fantini, J., Baghdiguian, S., Mabrouk, K., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *Proc. Natl. Acad. Sci. USA*, 92, 4867-4871 (1995).

95-5 Rôle des glycolipides dans l'infection des cellules par le virus du SIDA.

Fantini, J., Baghdiguian, S., Sabatier, J.-M., Yahi, N., *Journal Français des Oléagineux, Acides gras et Lipides*, 2, 104-107 (1995).

94-1 Structural and pharmacological diversity of scorpion neurotoxins.

Darbon, H., Sabatier, J.-M., *Current Topics in Peptide Protein Res.*, 1, (1994).

94-2 Des constructions peptidiques (SPC) inhibent l'entrée du VIH dans les cellules: Une nouvelle classe d'anti-rétroviraux.

Fantini, J., Yahy, N., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *Science, Technique et Technologie*, N° 26, 4-8 (1994).

94-3 Leiurotoxin I, a scorpion toxin specific for Ca^{2+} - activated K^+ channels: Structure-activity analysis using synthetic analogs.

Sabatier, J.-M., Fremont, V., Mabrouk, K., Crest, M., Darbon, H., Rochat, H., Van Rietschoten, J., Martin-Eauclaire, M.-F., *Int. J. Peptide Protein Res.*, 43, 486-495 (1994).

94-4 Evaluation of multi-branched peptides as inhibitors of HIV infection.

Yahy, N., Fantini, J., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *Letters in Peptide Science*, 1, 17-24 (1994).

94-5 Multi-branched peptide constructs (MBPC) of the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus-induced syncytium formation.

Benjouad, A., Fenouillet, E., Gluckman, J.-C., Sabatier, J.-M., *Antiviral Chemistry and Chemotherapy*, 5, 195-196 (1994).

94-6 Multi-branched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.

Yahy, N., Fantini, J., Mabrouk, K., Tamalet, C., De Micco, P., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *J. Virol.*, 68, 5714-5720 (1994).

94-7 Suramin inhibits binding of the V3 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 to galactosyl ceramide (GalCer).

Yahy, N., Sabatier, J.-M., Nickel, P., Mabrouk, K., Gonzalez-Scarano, F., Fantini, J., *J. Biol. Chem.*, 269, 24349-24353 (1994).

94-8 Multi-branched V3 peptides as HIV inhibitors.

Fantini, J., Yahy, N., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *Current Topics in Peptide Protein Res.*, 1, 11-24 (1994).

93-1 Multi-branched peptides based on the HIV-1 V3 loop consensus motif inhibit HIV-1 and HIV-2 infection in $CD4^+$ and $CD4^-$ cells.

Fantini, J., Yahy, N., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *C. R. Acad. Sci.*, 316, 1381-1387 (1993).

93-2 Solution structure of P05-NH2, a scorpion toxin analog with high affinity for apamin-sensitive potassium channel.

Meunier, S., Bernassau, J.-M., Sabatier, J.-M., Martin-Eauclaire, M.-F., Van Rietschoten, J., Cambillau, C., Darbon, H., *Biochemistry*, 32, 11969-11976 (1993).

93-3 P05, a new leiurotoxin I scorpion toxin: synthesis and structure-activity relationships of the α -amidated analog, a ligand of Ca^{2+} - activated K^+ channels with increased affinity.

Sabatier, J.-M., Zerrouk, H., Darbon, H., Mabrouk, K., Benslimane, A., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., *Biochemistry*, 32, 2763-2770 (1993).

93-4 Characterization of minor and major antigenic regions within the hepatitis B virus nucleocapsid (HBcAg).

Tordjman, M., Fontan, G., Rabillon, V., Martin, J., Trepo, C., Hoffenbach, A., Mabrouk, K., Sabatier, J.-M., Van Rietschoten, J., Somme, G., *J. Med. Virol.*, 41, 3221-3229 (1993).

93-5 Cytotoxic effect on lymphocytes of Tat from human immunodeficiency virus type 1.

Benjouad, A., Mabrouk, K., Moulard, M., Gluckman, J.-C., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *FEBS*, **319**, 119-124 (1993).

91-1 La protéine Nef du virus HIV-1 : facteur de controverse.

Sabatier, J.-M., Van Rietschoten, J., Granier, C., Bahraoui, E., *Médecine/Sciences*, **7**, 62-65 (1991).

91-2 Evidence for neurotoxic activity of Tat from human immunodeficiency virus type 1.

Sabatier, J.-M., Vives, E., Mabrouk, K., Benjouad, A., Rochat, H., Duval, A., Hue, B., Bahraoui, E., *J. Virol.*, **65**, 961-967 (1991).

91-3 Lethal neurotoxicity in mice of the basic domains of HIV and SIV Rev proteins: Study of these regions by circular dichroism.

Mabrouk, K., Van Rietschoten, J., Vives, E., Darbon, H., Rochat, H., Sabatier, J.-M., *FEBS*, **289**, 13-17 (1991).

90-1 Large fragments of Nef-protein and gp110 envelope glycoprotein from HIV-1 : synthesis, CD analysis and immunoreactivity.

Sabatier, J.-M., Fontan, G., Loret, E., Mabrouk, K., Rochat, H., Gluckman, J.-C., Montagnier, L., Granier, C., Bahraoui, E., Van Rietschoten, J., *Int. J. Peptide Protein Res.*, **35**, 63-72 (1990).

90-2 Immunogenicity and antigenicity of the human immunodeficiency virus (HIV) recombinant nef gene product. Mapping of T- and B-cell epitopes in immunized chimpanzees.

Bahraoui, E., Yagello, M., Billaud, J.-N., Sabatier, J.-M., Guy, B., Muchmore, E., Girard, M., Gluckman, J.-C., *AIDS Res. Hum. Retrovir.*, **6**, 1087-1098 (1990).

90-3 Relevance of anti-Nef antibodies detection as an early serological marker of HIV infection.

Bahraoui, E., Benjouad, A., Sabatier, J.-M., Allain, J.-P., Laurian, Y., Montagnier, L., Gluckman, J.-C., *Blood*, **76**, 257-264 (1990).

89-1 Identification of a common domain in calmodulin-activated eukaryotic and bacterial adenylate cyclases.

Goyard, S., Orlando, C., Sabatier, J.-M., Labruyère, E., D'Alayer, J., Fontan G., Van Rietschoten, J., Mock, M., Danchin, A., Ullmann, A., Monneron, A., *Biochemistry*, **28**, 1964-1967 (1989).

89-2 Convergent solid phase peptide synthesis VII. Good yields in the coupling of protected segments on a solid support.

Grandas, A., Albericio, F., Pedroso, E., Giralt, E., Sabatier, J.-M., Van Rietschoten, J., *Tetrahedron*, **45**, 4637-4648 (1989).

89-3 Use of synthetic peptides for the detection of antibodies against the Nef regulating protein in sera of HIV-infected patients.

Sabatier, J.-M., Clerget, B., Fontan, G., Fenouillet, E., Granier, C., Gluckman, J.-C., Rochat, H., Van Rietschoten, J., Montagnier, L., Bahraoui, E., *AIDS*, **3**, 215-220 (1989).

89-4 Accessibility of the highly conserved amino- and carboxy- terminal regions from HIV-1 external envelope glycoprotein.

Bahraoui, E., Clerget, B., Granier, C., Van Rietschoten, J., Sabatier, J.-M., Rochat, H., Gluckman, J.-C., Montagnier, L., *AIDS Res. Hum. Retrovir.*, **5**, 451-463 (1989).

87-1 Convergent solid phase peptide synthesis: recent progresses.

Van Rietschoten, J., Sabatier, J.-M., Tessier, M., Granier, C., Pedroso, E., Grandas, A., Albericio, F., Eritja, R., Nicolas, E., Josa, J., Giralt, E., *Protides of the Biological Fluids*, H. Peeters Ed., Pergamon Press, 1987, pp. 23-26.

87-2 Reduction and reoxidation of the neurotoxin II from the scorpion *Androctonus australis Hector*.

Sabatier, J.-M., Darbon, H., Fourquet, P., Rochat, H., Van Rietschoten, J., *Int. J. Peptide Protein Res.*, **30**, 125-134 (1987).

87-3 Convergent solid phase peptide synthesis VI: Syntheses by the Fmoc-amino acids with a modified protocol of two protected segments ; sequence 5-17 and 18-31 of the neurotoxin II of the scorpion *Androctonus australis Hector*.

Sabatier, J.-M., Tessier-Rochat, M., Granier, C., Van Rietschoten, J., Pedroso, E., Grandas, A., Albericio, F., Giralt, E., *Tetrahedron*, **43**, 5973-5980 (1987).

86-1 A specific immunological probe for the major myelin proteolipid; confirmation of a deletion in DM 20.

Trifilieff, E., Luu, B., Nussbaum, J.-L., Espinosa de los Monteros, A., Sabatier, J.-M., Van Rietschoten, J., *FEBS*, **198**, 235-239 (1986).

- PUBLICATIONS: (proceedings of congresses and symposia)
(published = 24)

01-1 Maurotoxin vs Pi1 scorpion toxins: towards new insights in the understanding of their distinct disulfide bridge patterns.

Fajloun, Z., Mosbha, A., Carlier, E., Mansuelle, P., Sandoz, G., Fathallah, M., di Luccio, E., Devaux, C., Van Rietschoten, J., Rochat, H., Darbon, H., De Waard, M., Sabatier, J.-M., In: «*Peptides 2000*», Proc. of the 26th Eur. Pept. Symp., J. Martinez and J.A. Fehrentz Eds, EDK Editions, 2001, pp 559-560.

01-2 Study on the in vitro oxidation/folding of Maurotoxin, a 4 disulfide-bridged scorpion toxin.

di Luccio, E., Azulay, D., Fajloun, Z., Mansuelle, P., Oughideni, R., Sampieri, F., Rochat, H., Van Rietschoten, J., De Waard, M., Sabatier, J.-M., In: «*Peptides 2000*», Proc. of the 26th Eur. Pept. Symp., J. Martinez and J.A. Fehrentz Eds, EDK Editions, 2001, pp 555-556.

01-3 Chemical synthesis and characterization of Maurocalcine, a scorpion toxin that activates Ca²⁺ release channel/ryanodine receptors.

Fajloun, Z., Kharrat, R., Mansuelle, P., Chen, L., Lecomte, C., di Luccio, E., Bichet, D., El Ayeb, M., Rochat, H., Allen, P.D., Pessah, I.N., De Waard, M., Sabatier, J.-M., In: «*Peptides 2000*», Proc. of the 26th Eur. Pept. Symp., J. Martinez and J.A. Fehrentz Eds, EDK Editions, 2001, pp 631-632.

01-4 Modeling of Lebetin peptides, a potent inhibitor of platelet aggregation: molecular dynamics and molecular mechanics studies.

Fathallah, M., Regaya, I., Camoin, L., Marrakchi, N., Sampol, J., El Ayeb, M., Rochat, H., Sabatier, J.-M., Mabrouk, K., In: «*Peptides 2000*», Proc. of the 26th Eur. Pept. Symp., J. Martinez and J.A. Fehrentz Eds, EDK Editions, 2001, pp 471-472.

01-5 Synthesis, ¹H-NMR structure and activity of a three disulfide-bridged Maurotoxin analog designed to restore the consensus motif of scorpion toxins.

Fajloun, Z., Ferrat, G., Carlier, C., Fathallah, M., Lecomte, C., Sandoz, G., di Luccio, E., Mabrouk, K., Legros, C., Darbon, H., Rochat, H., Sabatier, J.-M., De Waard, M., In: «*Peptides 2000*», Proc. of the 26th Eur. Pept. Symp., J. Martinez and J.A. Fehrentz Eds, EDK Editions, 2001, pp 629-630.

01-6 Ion channel activation by SPC3, a synthetic peptide inhibitor of HIV infection.

Mabrouk, K., Carlier, C., Fajloun, Z., Moulard, M., Rochat, H., Van Rietschoten, J., De Waard, M., Sabatier, J.-M., In: «*Peptides 2000*», Proc. of the 26th Eur. Pept. Symp., J. Martinez and J.A. Fehrentz Eds, EDK Editions, 2001, pp 923-924.

00-1 SPC3, an HIV-derived multibranch peptide, triggers an ionic conductance in *Xenopus* oocytes.

De Waard, M., Carlier, C., Fajloun, Z., Mabrouk, K., Sabatier, J.-M., In: « *Peptides for the new millenium* », Proc. of the 16th Am. Pept. Symp., G.B. Fields, J.P. Tam and G. Barany Eds, Kluwer Academic Publishers, 2000, pp 758-759.

99-1 A multiple branch peptide construction derived from a conserved sequence of the envelope glycoprotein gp41 inhibits human immunodeficiency virus infection.

Sabatier, J.-M., Moulard, M., Fenouillet, E., Rochat, H., Van Rietschoten, J., Mabrouk, K., ., In: "*Peptides : Frontiers of Peptide Science*", Proc. of the 15th Am. Pept. Symp., J.P. Tam and P. Kaumaya Eds, KLUWER/ESCOM, Kluwer Academic Publishers, 1999, pp 781-782.

98-1 Inhibition of HIV infection: Structure-activity study on synthetic multiple branch peptide from a cytoplasmic domain of the envelope glycoprotein gp41.

Mabrouk, K., Moulard, M., Rochat, H., Sabatier, J.-M., Van Rietschoten, J., Proc. of the 25th Eur. Pept. Symp., 1998.

98-2 3-D solution structure of Maurotoxin, a four disulfide bonds scorpion toxin from *Scorpio maurus* with high affinity for voltage-gated potassium channels.

Blanc, E., Sabatier, J.-M., Darbon, H., In: "*Peptides 1996*", Proc. of the 24th Eur. Pept. Symp., R. Ramage and R. Epton Eds, Mayflower Scientific Ltd., 1998, pp 265-266.

98-3 The first chemical synthesis of a short scorpion toxin cross-linked by four disulfide bridges, Maurotoxin.

Kharrat, R., Mabrouk, K., Crest, M., Darbon, H., Oughideni, R., Martin-Eauclaire, M.-F., Jacquet, G., El Ayeb, M., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., In: "*Peptides 1996*", Proc. of the 24th Eur. Pept. Symp., R. Ramage and R. Epton Eds, Mayflower Scientific Ltd., 1998, pp 537-538.

98-4 Synthesis and characterization of Leiurotoxin I analogs lacking one disulfide bridge.

Sabatier, J.-M., Lecomte, C., Mabrouk, K., Fremont, V., Darbon, H., Oughideni, R., Canarelli, S., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., In: "*Peptides 1996*", Proc. of the 24th Eur. Pept. Symp., R. Ramage and R. Epton Eds, Mayflower Scientific Ltd., 1998, pp 775-776.

96-1 SPC3, a synthetic peptide derived from the V3 domain of HIV-1 gp120, inhibits HIV-1 entry into CD4⁺ and CD4⁺ cells by two distinct mechanisms.

Yahi, N., Fantini, J., Baghdiguian, S., Mabrouk, K., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., In: "*Peptides: Chemistry, Structure and Biology*", Proc. of the 14th Am. Pept. Symp., P.T. Kaumaya and R.S. Hodges Eds, Mayflower Scientific Ltd., 1996, pp 780-781.

95-1 Multi-branched V3 peptides inhibit HIV infection in human lymphocytes and macrophages.

Yahi, N., Fantini, J., Mabrouk, K., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., In: "*Peptides 1994*", Proc. of the 23rd Eur. Pept. Symp., H.L. Maia Ed, Escom Science Publishers, 1995, pp 881-882.

94-1 Study on P05, a new leiurotoxin I-like scorpion toxin.

Sabatier, J.-M., Zerrouk, H., Darbon, H., Mabrouk, K., Benslimane, A., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., In: "*Peptides: Chemistry, Structure, and Biology*", Proc. of the 13th Am. Pept. Symp., R.S. Hodges and J.A. Smith Eds, Escom Science Publishers, 1994, pp 520-522.

93-1 Structure-toxicity relationships study of the basic domains of HIV and SIV Rev proteins.

Mabrouk, K., Van Rietschoten, J., Vives, E., Darbon, H., Rochat, H., Sabatier, J.-M., In: "*Peptides 1992*", Proc. of the 22nd Eur. Pept. Symp., G.H. Schneider and A.N. Eberle Eds, Escom Science Publishers, 1993, pp 891-893.

92-1 Evidence for neurotoxic activity of Tat from human immunodeficiency virus type 1.

Sabatier, J.-M., Vives, E., Mabrouk, K., Benjouad, A., Rochat, H., Duval, A., Hue, B., Van Rietschoten, J., Bahraoui, E., In: "*Peptides 1991*", Proc of the 12th Am. Pept. Symp., J. Smith and J. Rivier Eds, Escom Leiden, 1992, pp 707-708.

91-1 Synthetic peptides as antigens for detection by ELISA of anti-HBc antibodies in patients infected by Hepatitis B virus (HBV).

Fontan, G., Tordjman, M., Sabatier, J.-M., Mabrouk, K., Offenbach, A., Martin, J., Van Rietschoten, J., Sommé, G., In: "*Peptides 1990*", Proc. of the 21th Eur. Pept. Symp., E. Giralt and D. Andreu Eds, Escom Science Publishers, 1991, pp 903-904.

90-1 Prevalence of anti-Nef positive sera in HIV-infected patients: mapping of the major epitopes of Nef-protein using synthetic peptides.

Sabatier, J.-M., Van Rietschoten, J., Granier, C., Gluckman, J.-C., Montagnier, L., Bahraoui, E., In: "*Peptides: Chemistry, Structure and Biology*", Proc. of the 11th Am. Pept. Symp., J. Rivier and G.R. Marshall Eds, Escom, Leiden, 1990, pp 847-848.

89-1 Coupling of peptide segments in convergent solid phase peptide synthesis.

Grandas, A., Albericio, F., Pedroso, E., Giralt, E., Sabatier, J.-M., Van Rietschoten, J., In: "*Peptides 1988*", Proc. of the 20th Eur. Pept. Symp., G. Jung and E. Bayer Eds, Walter de Gruyter, Berlin-New York, 1989, pp 160-162.

89-2 Probing of macromolecular structures by site specific antibodies: a few successes.

Granier, C., Bahraoui, E., Fourquet, P., Sabatier, J.-M., Fontan, G., Céard, B., Labbé-Jullié, C., Van Rietschoten, J., In: "*Second Forum on Peptides*", A. Aubry, M. Marraud, B. Vitoux Eds., INSERM/J. Libbey Eurotext Ltd., 1989, 174, pp 189-192.

89-3 Solid phase segments coupling; quality control by automated Edman degradation of peptidyl-resin.

Van Rietschoten, J., Sabatier, J.-M., Paroutaud, P., Albericio, F., Grandas, A., Pedroso, E., Giralt, E., In: "*Second Forum on Peptides*", A. Aubry, M. Marraud, B. Vitoux Eds., INSERM/J. Libbey Eurotext Ltd., 1989, 174, pp 215-219.

88-1 Reoxidation of basic insoluble reduced proteins: example of scorpion neurotoxin II of *Androctonus australis Hector*.

Sabatier, J.-M., Darbon, H., Fourquet, P., Rochat, H., Van Rietschoten, J., In: "*Peptides, Chemistry and Biology*", Proc. of the 10th Am. Pept. Symp., G.R. Marshall Ed., Escom, Leiden, 1988, pp 379-380.

87-1 Solid phase synthesis with Fmoc-amino acids: an alternative protocol.

Van Rietschoten, J., Fourquet, P., Sabatier, J.-M., Granier, C. In: "*Peptides 1986*", Proc. of the 19th Eur. Pept. Symp., D. Theodoropoulos Ed., Walter de Gruyter, Berlin-New York, 1987, pp 179-182.

- Poster and oral reports (congress - symposium)
(presented = 177)

21-1 Mode of action of SARS-CoV-2, RAS & vitamin D.

Sabatier, J.-M., Institut de Recherche des Terres Arides (Tunisie), 2021.

21-2 Mode of action of SARS-CoV-2 & vitamin D.

Sabatier, J.-M., University of Carthage, Centre de Biotechnologie de Borjcedria (Tunisie), 2021.

20-1 In vitro survey of designed Melittin's derived peptides.

Hakemi-Vala, M., Akbari, R., Bagheri, K.P., Sabatier, J.-M., Bavalian, P., Pashaei, F., Hashemi, A., 30th European Congress of Clinical Microbiology and Infectious Diseases, Paris (France), 2020.

- 19-1 **Survey of pharmacological synergism of melittin with antibiotics against multi-drug resistant *P. aeruginosa* and *A. baumannii*.**
Akbari, R., Hakemi-Vala, M., Bagheri, K.P., Sabatier, J.-M., Hashemi, A., Pashaei, F., Bavalian, P., 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam (Pays-Bas), 2019.
- 19-2 **Designing and screening melittin's derivative peptides and evaluation of their antibacterial activity and toxicity in cell.**
Akbari, R., Hakemi-Vala, M., Bagheri, K.P., Sabatier, J.-M., Hashemi, A., 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam (Pays-Bas), 2019.
- 16-1 **Contribution of peptide synthesis in the study of animal toxins: a few examples.**
Sabatier, J.-M., MATI meeting, International Network of the Pasteur Institutes, Téhéran (Iran), 2016.
- 15-1 **Tat Oyi-based candidate therapeutic vaccine: a successful phase 1 clinical trial in HIV-1 infected patients.**
Escaich, S., Sabatier, J.-M., De Mareuil, J., *Retrovirus and Novel Drugs*, Chicago (USA), 2015.
- 14-1 **NADPH oxidase as a target to control pathological cell motility.**
Mousslim, M., Pagano, A., Andreotti, N., Culcasi, M., Thuault, S., Parat, F., Luis, J., Sadok, A., Pietri, S., Sabatier, J.-M., Kovacic, H., 5th French Cell Adhesion Club Symposium, Marseille (France), 2014.
- 14-2 **NADPH oxidase as a target to control pathological cell motility.**
Mousslim, M., Pagano, A., Andreotti, N., Culcasi, M., Thuault, S., Parat, F., Luis, J., Sadok, A., Pietri, S., Sabatier, J.-M., Kovacic, H., *Gordon Research Conference on Nox Family NADPH Oxidases*, Lucca (Italy), 2014.
- 14-3 **Scorpion toxin-derived peptides as candidate therapeutic drugs.**
Sabatier, J.-M., *International Academic Lecture*, University of Ismaïlia (Egypt), 2014.
- 14-4 **Characterization of two Moroccan scorpion venoms: proteomic analysis, neurotoxicity, myotoxicity and sensitivity to neutralization by commercial polyclonal antivenom.**
Oukkache, N., Rusmili, M.R., Othman, I., Ghalim, N., Chgoury, F., Boussadda, L., El Mdaghri, N., Sabatier, J.-M., 22nd Meeting on Toxinology, 'Toxins: new targets and new functions', Paris (France), 2014.
- 13-1 **Two arginine residues from the SK3 channel outer vestibule controls selectivity of recognition by scorpion toxins.**
Feng, J., Hu, Y., Yi, H., Yin, S., Han, S., Hu, J., Chen, Z., Yang, W., Cao, Z., De Waard, M., Sabatier, J.-M., Li, W., Wu, Y., 11th Chinese Meeting on Toxins and Their Applications, Qing Dao (China), 2013.
- 12-1 **Design of novel membrane channel specific ligands.**
Sabatier, J.-M., *International Academic Lectures on Frontier Molecular Physiology*, Shanghai (China), 2012.
- 12-2 **Apport de la RMN et de la modélisation moléculaire pour la conception de nouveaux médicaments.**
Mosbah, A., Abbour, S., Fajloun, Z., Andreotti, N., de Lamballerie, X., Baudy-Floch, M., Sabatier, J.-M., ATSB Congress, Hammamet (Tunisia), 2012.
- 12-3 **Peptide-based competitive enzyme-linked immunosorbent assay and magnetic protein A beads for analysis of Ochratoxin A, in red wine.**

Hadj Hassine, I., Andreotti, N., Sabatier, J.-M., Gonzalez, C., Bazin, I., *XVIIème Rencontres Transfrontalières Capteurs et Biocapteurs*, Tarragona (Spain), 2012.

1st Prize (best scientific advance).

12-4 Peptide binding to Ochratoxin A mycotoxin: a new approach in conception of biosensors.

Bazin, I., Andreotti, N., Hadj Hassine, I., De Waard, M., Sabatier, J.-M., Gonzalez, C., *XIIIth World Congress on Biosensors*, Cancun (Mexico), 2012.

11-1 Identification of peptides which bind to the mycotoxin Ochratoxin A used in future biosensor.

Bazin, I., Hadj Hassine, I., Andreotti, N., Sabatier, J.-M., Gonzalez, C., *XVIème Rencontres Transfrontalières Capteurs et Biocapteurs*, Toulouse (France), 2011.

08-1 Solid-phase synthesis, a biotechnological approach for structure-activity relationships of scorpion toxins: innovative strategy of chemical synthesis of Maurotoxin with constrained disulfide bridging.

M'Barek, S., Sampieri, F., Sabatier, J.-M., *International Symposium on Biotechnology*, Sfax (Tunisia), 2008.

08-2 Les toxines de scorpion : « outils » en Neurosciences.

M'Barek, S., Sampieri, F., Sabatier, J.-M., *IVème Journées de Neurosciences*, Tunis (Tunisia), 2008.

06-1 Blockade of neural voltage-gated K⁺ channels applied to neuroinflammatory disease therapy.

Beraud, E., Viola, A., Regaya, I., Confort-Gouny, S., Siaud, P., Ibarrola, D., Le Fur, Y., Barbaria, J., Pellissier, J.-F., Sabatier, J.-M., Medina, I., Cozzone, P., *14ème Rencontres en Toxinologie : « Toxines et Cancer »*, Paris (France), 2006.

06-2 Scorpion toxins active on potassium channels: a new field for cancer treatment ?

Mouhat, S., Visan, V., Ananthakrishnan, S., Wulff, H., Andreotti, S., Grissmer, S., Darbon, H., De Waard, M., De Waard, M., De Rougé, B., Sabatier, J.-M., *14ème Rencontres en Toxinologie : « Toxines et Cancer »*, Paris (France), 2006.

05-1 Les toxines de scorpion comme modèles moléculaires pour l'étude du processus de repliement et d'oxydation in vitro des protéines.

Sabatier, J.-M., *14^{ème} Réunion Peptides et Protéines*, Aussois (France), 2005. Conférencier invité.

05-2 RLmb, une nouvelle construction peptidique dérivée de la glycoprotéine transmembranaire gp41 du VIH : synthèse chimique et activité anti-virale.

Sabatier, J.-M., Moulard, M., Doria, E., Mouhat, S., Guieu, R., De Waard, M., Mabrouk, K., *14^{ème} Réunion Peptides et Protéines*, Aussois (France), 2005.

05-3 Un tripeptide isolé du venin *Cerastes cerastes* inhibe fortement l'agrégation plaquettaire : purification, synthèse et caractérisation biologique.

Mabrouk, K., Marrakchi, N., Sabatier, J.-M., Rochat, H., Guieu, R., El Ayeb, M., *14^{ème} Réunion Peptides et Protéines*, Aussois (France), 2005.

05-4 Etude de relations structure-fonction d'une toxine de scorpion active sur les canaux K⁺ : Conception et stratégie innovante de synthèse d'une Maurotoxine avec un appariement conventionnel des ponts disulfure.

M'Barek, S., Fajloun, Z., El Ayeb, M., Sampieri, F., Sabatier, J.-M., *16^{ème} Journées Biologiques de l'ATSB*, Hammamet (Tunisie), 2005.

05-5 Mechanism of drug resistance in Hepatitis C: the case of protease inhibitor BILN-2061.

Courcambeck, J., Perbost, R., Chabaud, P., Pèpe, G., Bouzidi, M., Mabrouk, K., Sabatier, J.-M., Halfon, P., *40th Annual Meeting of the European Association for the Study of Liver*, Paris (France), 2005.

- 05-6 Molecular susceptibility profile of BILN-2061 to various Hepatitis C virus genotypes: a narrow genotype spectrum?**
Courcambeck, J., Perbost, R., Chabaud, P., Pèpe, G., Bouzidi, M., Mabrouk, K., Sabatier, J.-M., Halfon, P., *40th Annual Meeting of the European Association for the Study of Liver*, Paris (France), 2005.
- 05-7 Cell penetration properties of maurocalcine: a new efficient peptide vector for cell entry of proteins and nanoparticles.**
Leon, L., Boisseau, S., Molière, B., Grunwald, D., Collin, V., Sabatier, J.-M., Ronjat, M., Mabrouk, K., De Waard, M., *Pepvec, Satellite Meeting of the Joint 15th IUPAB & 5th EBSA International Biophysics Congress*, Montpellier (France), 2005; Prix du meilleur poster.
- 05-8 Entry inhibitor GNS037 exhibits potent anti-HIV activity in vitro.**
Halfon, P., Sabatier, J.-M., Perbost, R., Jouirou, B., Cacoub, P., Lavilette, D., Cosset, F.-L., *56th Annual Meeting of the American Association for the Study of Liver Diseases*, San Francisco (U.S.A.), 2005.
- 04-1 Repliement et oxydation de peptides complexes.**
Sabatier, J.-M., *Atelier Technologique INSERM « Du peptide naturel au médicament »*, La Grande Motte (France), 2004. Conférencier invité.
- 04-2 Purification et caractérisation de la lacticine LC14, une bactériocine sécrétée par une souche locale de Lactococcus lactis BMG6.14.**
Lasta, S., Ouzari, H.I., Sabatier, J.-M., Boudabous, A., *Premier Séminaire de Microbiologie*, Hammamet (Tunisie), 2004.
- 04-3 Molecular mechanism susceptibility profile of BILN-2061 to various hepatitis C virus genotypes and NS3-NS4A protease inhibitor mutation: D168A and D168V.**
Courcambeck, J., Perbost, R., Chabaud, P., Pepe, G., Bouzidi, M., Mabrouk, K., Sabatier, J.-M., Halfon, P., *The Liver Meeting, 55th Annual Meeting of the American Association for the study of Liver Diseases*, Boston, MA (U.S.A.), 2004.
Hepatology 40 (4) : 385A Suppl. 1, Oct. 2004.
- 03-1 Etude de relations structure-fonction de toxines courtes de scorpion à l'aide de chimères synthétiques.**
M'Barek, S., Fajloun, Z., Mosbah, A., Di Luccio, E., Mansuelle, P., Rochat, H., Sampieri, F., Sabatier, J.-M., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.
- 03-2 Synthesis, 3-D structure, and pharmacology of a reticulated chimeric peptide derived from Maurotoxin and Tsk scorpion toxins.**
Fajloun, Z., Ferrat, E., Carlier, E., M'Barek, S., Regaya, I., Fathallah, M., Rochat, H., Darbon, H., De Waard, M., Sabatier, J.-M., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.
- 03-3 Synthesis and pharmacological characterization of structural analogs of Maurocalcine, a scorpion toxin active on calcium channel/ryanodine receptor (RyR).**
Estève, E., Ronjat, M., De Waard, M., Rochat, H., Sabatier, J.-M., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.
- 03-4 Kinetics, structural and electrophysiological studies of the in vitro folding/oxidation of Maurotoxin, a four disulfide-bridged scorpion toxin.**
Di Luccio, E., Opi, S., Sandoz, G., M'Barek, S., Carlier, E., Matavel, A., Rochat, H., Loret, E., De Waard, M., Sabatier, J.-M., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003 ; Prix du meilleur poster.
- 03-5 Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K⁺ channel, SKCa2.**

Regaya, I., Shakkottai, V.G., Wulff, H., Fajloun, Z., Tomita, H., Fathallah, M., Cahalan, M.D., Gargus, J.J., Chandy, K.G., Sabatier, J.-M., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.

03-6 Synthèse chimique et caractérisation pharmacologique d'analogues de la Leiurotoxine I, une toxine de scorpion active sur les canaux SKCa.

Andreotti, N., Regaya, I., Fajloun, Z., Rochat, H., Chandy, K.G., Devaux, C., Sabatier, J.-M., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.

03-7 Maurotoxin, a potent inhibitor of intermediate conductance Ca²⁺-activated potassium channels.

Fajloun, Z., Castle, N.A., London, D.O., Creech, C., Stocker, J.W., Sabatier, J.-M., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.

03-8 Des modifications lipophiles de la molécule SPC3 augmentent son activité anti-VIH.

Sabatier, J.-M., Rangeva, M.-P., Doria, E., De Mareuil, J., Van Rietschoten, J., Rochat, H., Gras-Masse, H., Mabrouk, K., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.

03-9 CsslV, une toxine de scorpion active sur les canaux sodium potentiel-dépendants : Synthèse et caractérisation pharmacologique.

Cestèle, S., Jouirou, B., Devaux, C., Mansuelle, P., Sampieri, F., Rochat, H., Sabatier, J.-M., Mabrouk, K., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.

03-10 Les Lébétines, peptides inhibiteurs de l'aggrégation plaquettaire : Synthèse chimique, activité biologique et étude structurale par RMN.

Mosbah, A., Jouirou, B., Fathallah, M., Gonzales, M.J., Marrakchi, N., El Ayeb, M., Giralt, E., Van Rietschoten, J., Camoin, L., Sampol, J., Rochat, H., Sabatier, J.-M., Darbon, H., Mabrouk, K., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.

03-11 Conception, synthèse par voie chimique, caractérisation pharmacologique et structure 3-D d'une mini-Maurotoxine.

Jouirou, B., Mosbah, A., De Waard, M., Lopez-Gonzales, I., Fathallah, M., Devaux, C., Cestèle, S., Mansuelle, P., Kharrat, R., El Ayeb, M., Rochat, H., Sabatier, J.-M., Mabrouk, K., *5ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2003.

03-12 Maurotoxin, a molecular model of scorpion toxin engineering.

Rochat, H., Sabatier, J.-M., *14th World Congress on Animal, Plant and Microbial Toxins*, Adelaide (Australie), 2003.

03-13 Design and synthesis of pharmacologically selective scorpion toxin-derived peptides: therapeutic potential in experimental autoimmune encephalomyelitis.

Regaya, I., Andreotti, N., Ferrat, G., Beeton, C., di Luccio, E., Darbon, H., Chandy K.G., Béraud, E., Sabatier, J.-M., *Conférences François Lhermitte, 13^{ème} Réunion de l'ARSEP*, Paris (France), 2003.

03-14 La maurotoxine, un modèle moléculaire d'ingénierie de toxines de scorpion : stratégie innovante de sa synthèse avec un appariement conventionnel des ponts disulfure.

M'Barek, S., Lopez-Gonzalez, I., Andreotti, N., di Luccio, E., Visan, V., Grissmer, S., Judge, S., El Ayeb, M., Darbon, H., Rochat, H., Sampieri, F., Fajloun, Z., De Waard, M., Sabatier, J.-M., *11ème Rencontres en Toxinologie : « Toxinogénèse naturelle, toxinogénèse anthropique »*, Paris (France), 2003.

03-15 Synthèse chimique et caractérisation pharmacologique de Pi4, une toxine de scorpion isolée du venin du scorpion *Pandinus imperator*, active sur les canaux potassium.

M'Barek, S., Mosbah, A., Sandoz, G., Mansuelle, P., Fajloun, Z., Possani, L., Rochat, H., Sampieri, F., Delepierre, M., De Waard, M., Sabatier, J.-M., *11ème Rencontres en Toxinologie : « Toxinogénèse naturelle, toxinogénèse anthropique »*, Paris (France), 2003.

03-16 Conception, synthèse chimique et caractérisation d'une chimère à 5 ponts disulfure dérivée de la Butantoxine et la Maurotoxine, deux toxines de scorpion actives sur les canaux potassium.

M'Barek, S., Andreotti, N., di Luccio, E., Visan, V., Chagot, B., Mansuelle, P., Grissmer, S., Rochat, H., El Ayeb, M., Marrakchi, M., Sampieri, F., Darbon, H., Sabatier, J.-M., Fajloun, Z., *11ème Rencontres en Toxinologie : « Toxinogénèse naturelle, toxinogénèse anthropique »*, Paris (France), 2003.

03-17 Première synthèse chimique et caractérisation d'une toxine longue de scorpion : la toxine 1 d'Androctonus australis hector (Aah1), active sur les canaux sodium.

M'Barek, S., Fajloun, Z., Devaux, C., Mansuelle, P., Cestèle, S., Rochat, H., El Ayeb, M., Sabatier, J.-M., Sampieri, F., *11ème Rencontres en Toxinologie : « Toxinogénèse naturelle, toxinogénèse anthropique »*, Paris (France), 2003.

03-18 Elementary calcium release events (ECRE) in the presence of the scorpion toxin maurocalcine.

Csernoch, L., Szappanos, H., Cseri, J., Gonczi, M., Sabatier, J.-M., Altafaj, X., De Waard, M., Ronjat, H., *47th Annual Meeting of the Biophysical Society*, Baltimore (U.S.A.), 2003.

Biophys. J. 86 (1): 579A Part 2, Suppl. S, Jan. 2004.

03-19 Is the block of current through voltage-gated Kv1.2 channels by maurotoxin pH dependent?

Visan, V., Sabatier, J.-M., Grissmer, S., *47th Annual Meeting of the Biophysical Society*, Baltimore (U.S.A.), 2003.

Biophys. J. 86 (1) : 538A Part 2, Suppl. S, Jan. 2004.

03-20 Identification of the maurocalcine and domain a of the II-III loop of DHPR Ca(v)1.1 alpha subunit binding sites on skeletal ryanodine receptor.

Altafaj, X., Esteve, E., Cheng, W., Brocard, J.U., Coronado, R., Jona, I., Sabatier, J.-M., De Waard, M., Ronjat, H., *47th Annual Meeting of the Biophysical Society*, Baltimore (U.S.A.), 2003.

Biophys. J. 86 (1) : 429A-430A Part 2, Suppl. S, Jan. 2004.

03-21 Effect of maurocalcine on the calcium release channel.

Szegedi, C., Almassy, J., Sabatier, J.-M., Jona, I., *47th Annual Meeting of the Biophysical Society*, Baltimore (U.S.A.), 2003.

Biophys. J. 86 (1) : 224A Part 2, Suppl. S, Jan. 2004.

02-1 Lei-Dab7, a selective blocker of the small conductance calcium-activated K⁺ channel, SKCa2.

Regaya, I., Shakkottai, V.G., Fajloun, Z., Sabatier, J.-M., Chandry, K.G., Rochat, H., *12ème Réunion du Groupe Français des Peptides et Protéines*, Aussois (France), 2002.

02-2 Synthèse chimique et caractérisation de Pi4, une toxine de scorpion courte isolée du venin du scorpion *Pandinus imperator*, et active sur les canaux potassium.

M'Barek, S., Fajloun, Z., Rochat, H., Sampieri, F., Delepierre, M., Sabatier, J.-M., *12ème Réunion du Groupe Français des Peptides et Protéines*, Aussois (France), 2002.

02-3 Synthesis, 3-D structure and pharmacology of a chimeric peptide derived from Maurotoxin and Tsk scorpion toxins.

Fajloun, Z., Ferrat, G., Carlier, E., M'Barek, S., Regaya, I., Fathallah, M., Rochat, H., Darbon, H., De Waard, M., Sabatier, J.-M., *12ème Réunion du Groupe Français des Peptides et Protéines*, Aussois (France), 2002.

02-4 Synthèse et caractérisation pharmacologique d'analogues structuraux de la Maurocalcine, une toxine de scorpion active sur les canaux calcium ryanodine-sensibles.

Estève, E., Sabatier, J.-M., Rochat, H., *12ème Réunion du Groupe Français des Peptides et Protéines*, Aussois (France), 2002.

02-5 Kinetics, structural and electrophysiological studies of the in vitro folding/oxidation of Maurotoxin, a four disulfide-bridged scorpion toxin.

Di Luccio, E., Rochat, H., De Waard, M., Sabatier, J.-M., 12ème Réunion du Groupe Français des Peptides et Protéines, Aussois (France), 2002.

02-6 Synthèse et caractérisation pharmacologique de CsslV, une toxine de scorpion active sur les canaux sodium potentiel-dépendants.

Cestèle, S., Jouirou, B., Mansuelle, P., Rochat, H., Sabatier, J.-M., Mabrouk, K., 12ème Réunion du Groupe Français des Peptides et Protéines, Aussois (France), 2002.

02-7 MMFII, une nouvelle bactériocine isolée de lactocoques de dérivés laitiers : Synthèse et caractérisations structurale et biologique.

Ferchichi, M., Fathallah, M., Mansuelle, P., Rochat, H., Sabatier, J.-M., Manai, M., Mabrouk, K., 12ème Réunion du Groupe Français des Peptides et Protéines, Aussois (France), 2002.

02-8 Des modifications lipophiles de la molécule SPC3 augmentent son activité anti-VIH.

Sabatier, J.-M., Rangeva, M.-P., Doria, E., Van Rietschoten, J., Rochat, H., Mabrouk, K., 12ème Réunion du Groupe Français des Peptides et Protéines, Aussois (France), 2002.

02-9 Etude des relations structure-activité des lébétines, peptides inhibiteurs de l'aggrégation plaquettaire.

Fathallah, M., Regaya, I., Gonzales, M.J., Marrakchi, N., El Ayeb, M., Giralt, E., Van Rietschoten, J., Sabatier, J.-M., Mabrouk, K., 12ème Réunion du Groupe Français des Peptides et Protéines, Aussois (France), 2002.

02-10 Traitement de l'Encéphalomyélite Autoimmune Expérimentale à l'aide de bloqueurs peptidiques des canaux potassium.

Beeton, C., Wulff, H., Barbaria, J., Clot-Faybesse, O., Pennington, M., Sabatier, J.-M., Cahalan, M.D., Chandy, K.G., Béraud, E., 12ème Réunion du Groupe Français des Peptides et Protéines, Aussois (France), 2002.

02-11 Kinetics, structural and electrophysiological studies of the in vitro folding/oxidation of Maurotoxin, a four disulfide-bridged scorpion toxin.

Di Luccio, E., Rochat, H., De Waard, M., Sabatier, J.-M., 1st International Conference on Biomedical Spectroscopy, Cardiff (U.K.), 2002.

02-12 Action de la maurocalcine (sMCa), une toxine de scorpion, sur les récepteurs sensibles à la ryanodine (RyR) régulant les réserves de calcium du réticulum sarcoplasmique.

Estève, E., Sabatier, J.-M., Ronjat, M., De Waard, M., Rochat, H., Colloque "Canaux Ioniques", 13ème Edition, La Londe les Maures (France), 2002.

02-13 New laminin-peptide promotes extracellular matrix production and modulates cell adhesion.

Bauza, E., Perrin, A., Cucumel, K., Dal Farra, C., Botto, J.-M., Portolan, F., Sabatier, J.-M., Domloge, N., Society for Investigative Dermatology, Philadelphie (U.S.A.), 2002.

02-14 A new fibronectin peptide that enhances epidermal cell adhesion

Dal Farra, C., Bauza, E., Perrin, A., Botto, J.-M., Portolan, F., Sabatier, J.-M., Domloge, N., 20th World Congress of Dermatology, Paris (France), 2002.

02-15 Etude des relations structure-fonction de la Maurotoxine.

di Luccio, E., Fajloun, Z., Mouhat, S., Darbon, H., Rochat, H., De Waard, M., Sabatier, J.-M., 10ème Rencontres en Toxinologie, "Toxines et Recherches Biomédicales", Paris (France), 2002.

02-16 **Synthèse et caractérisation pharmacologique d'analogues structuraux de la Maurocalcine, une toxine de scorpion active sur les canaux calcium ryanodine-sensibles.**

Estève, E., Ronjat, M., Rochat, H., De Waard, M., Sabatier, J.-M., Colloque "Canaux Ioniques", 13ème Edition, Presqu'île de Giens (France), 2002.

02-17 **Kinetics, structural and electrophysiological studies of the in vitro folding/oxidation of Maurotoxin, a four disulfide-bridged scorpion toxin.**

Di Luccio, E., Rochat, H., De Waard, M., Sabatier, J.-M., Colloque "Canaux Ioniques", 13ème Edition, Presqu'île de Giens (France), 2002.

02-18 **Synthèse chimique et caractérisation de Pi4, une toxine courte isolée du venin de scorpion *Pandinus imperator* et active sur les canaux potassium.**

M'Barek, S., Fajloun, Z., Rochat, H., Sampieri, F., Delepierre, M., Sabatier, J.-M., 27th World Veterinary Congress, Tunis (Tunisie), 2002.

02-19 **New laminin-peptide promotes extra-cellular matrix production and modulates cell adhesion.**

Bauza, E., Cucumel, K., Dal Farra, C., Botto, J.-M., Portolan, F., Sabatier, J.-M., Domloge, N. 2nd International Symposium, The Science and Technology of Skin Aging, Cleveland (U.S.A.), 2002.

02-20 **Maurotoxin block of intermediate conductance, calcium-activated potassium channel, IKCa1, is pH dependent.**

Visan, V., Sabatier, J.-M., Grissmer, S., 46th Annual Meeting of the Biophysical Society, San Antonio (U.S.A.), 2002.

Biophys. J. 84 (2): 238A Part 2, Suppl. S, Feb. 2003.

02-21 **Maurocalcine (MCa) modulates ryanodine receptor activity and Ca²⁺ release in muscle cells.**

Estève, E., Smida-Rezgui, S., Marty, I., Jona, I., Sabatier, J.-M., Rochat, H., Chen, L., Allen, P., Pessah, I., De Waard, M., Sorrentino, V., Ronjat, M., 46th Annual Meeting of the Biophysical Society, San Antonio (U.S.A.), 2002.

Biophys. J. 84 (2): 557A Part 2, Suppl. S, Feb. 2003.

02-22 **Role of blockade of neuronal and lymphocyte voltage-gated potassium channels (Kv) in experimental autoimmune encephalomyelitis therapy.**

Ferrat, G., Judge, S., Regaya, I., Medina, J., Safronov, B., Bernard, D., Sabatier, J.-M., Béraud, E., Conférences François Lhermitte, 12^{ème} Réunion de l'ARSEP, Paris (France), 2002.

01-1 **Maurotoxin, a potent inhibitor of the intermediate conductance calcium-activated potassium channel IK1.**

Castle, N., Creech, C., Sabatier, J.-M., Biophysical Society, 45th Annual Meeting, Boston (U.S.A.), 2001.

Biophys. J. 80 (1): 808 Part 2, Jan. 2001.

01-2 **Selective blocking of K⁺ channels ameliorates experimental auto-immune encephalomyelitis.**

Beeton, C., Wulff, H., Barbaria, J., Crest, C., Sabatier, J.-M., Pennington, M., Cahalan, M.D., Chandy, K.G., Béraud, E., Biophysical Society, 45th Annual Meeting, Boston (U.S.A.), 2001.

Biophys. J. 80 (1): 1846 Part 2, Jan. 2001.

01-3 **Maurotoxin and Pi1 scorpion toxins as molecular models to study the selectivity of half-cystine pairings during in vitro folding/oxidation.**

Fajloun, Z., Carlier, E., Mansuelle, P., Regaya, I., Ferrat, G., Kharrat, R., di Luccio, E., Sandoz, G., El Ayeb, M., Darbon, H., Rochat, H., De Waard, M., Sabatier, J.-M., 4^{ème} Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires, Marseille (France), 2001.

01-4 **L'efficacité de l'antiviral SPC3 contre l'infection des lymphocytes humains par le VIH est augmentée lors de son encapsulation dans des liposomes.**

De Mareuil, J., Mabrouk, K., Doria, E., Moulard, M., De Chasteigner, S., Ranjeva, M.-P., Rochat, H., Sabatier, J.-M., *4ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2001.

01-5 Etude in vitro du processus de repliement/oxydation de la Maurotoxine, une toxine de scorpion réticulée par 4 ponts disulfure.

Di Luccio, E., Azulay, D.-O., Fajloun, Z., Mansuelle, P., Oughideni, R., Rochat, H., Sabatier, J.-M., *4ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2001.

01-6 Etude des relations structure-activité des peptides cycliques des Lébétines : synthèse, modélisation moléculaire et activité anti-agrégante.

Regaya, I., Fathallah, M., Camoin, L., Marrakchi, N., Sampol, L., El Ayeb, M., Rochat, H., Sabatier, J.-M., Mabrouk, K., *4ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2001.

01-7 Pharmacocinétique d'une construction synthétique polymérique (SPC3) capable d'inhiber l'infection de cellules humaines par le VIH.

Esteve, E., Devaux, C., Juin, M., Sabatier, J.-M., *4ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2001.

01-8 La boucle cytoplasmique I-II des canaux calciques voltage-dépendants contrôle leur inactivation de manière β dépendante.

Geib, S., Sandoz, G., Cornet, V., Mabrouk, K., Fund-Saunier, O., Bichet, D., Restituto, S., Hoshi, T., Sabatier, J.-M., De Waard, M., *4ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 2001.

01-9 Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K^+ channel, SKCa2.

Shakkottai, V., Regaya, I., Wulff, H., Fajloun, Z., Tomita, H., Fathallah, M., Cahalan, M., Gargus, J.J., Sabatier, J.-M., Chandy, K.G., *Biophysical Society, 45th Annual Meeting*, Boston (U.S.A.), 2001.
Biophys. J. 82 (1): 2855 Part 2, Jan. 2002.

01-10 Maurotoxin and apamin in combination abolish EDHF-mediated relaxation of the rat mesentery artery.

Hinton, J.M., Sabatier, J.-M., Langton, P.D., *Biophysical Society, 45th Annual Meeting*, Boston (U.S.A.), 2001.
Biophys. J. 82 (1) : 2740 Part 2, Jan. 2002.

01-11 Are SKCa channels expressed in endothelial cells of the rat small mesenteric artery?

Langton, P.D., Sabatier, J.-M., Hinton, J.M., *Biophysical Society, 45th Annual Meeting*, Boston (U.S.A.), 2001.
Biophys. J. 82 (1): 2737 Part 2, Jan. 2002.

01-12 Development of a new fibronectin peptide, and its effect on epidermal cell adhesion.

Dal Farra, C., Bauza, E., Botto, J.-M., Portolan, F., Sabatier, J.-M., Domloge, M., *41th Am. Soc. for Cell Biol. Ann. Meeting*, Washington D.C. (U.S.A.).
Molecular Biol. Cell, 12:S , 1033 Suppl. S, Nov. 2001.

01-13 Synthèse et caractérisation pharmacologique d'analogues structuraux de la Maurocalcine, une toxine de scorpion active sur les canaux calcium ryanodine-sensibles.

Estève, E., Sabatier, J.-M., Fajloun, Z., De Waard, M., Allen, P.D., Rochat, H., *Journée du Réseau d'Etude du Médicament*, Marseille (France), 2001.

00-1 Towards new insights in the understanding of disulfide bridge formation in Maurotoxin.

Sandoz, G., Carlier, E., Fajloun, Z., di Luccio, E., Mosbah, A., Fathallah, M., Mansuelle, P., Rochat, H., Darbon, H., Sabatier, J.-M., De Waard, M., *Colloque "Canaux Ioniques"*, 11ème Edition, La Londe les Maures (France), 2000.

00-2 *Maurotoxin vs Pi1 scorpion toxins: towards new insights in the understanding of their distinct disulfide bridge patterns.*

Rochat, H., Fajloun, Z., Carlier, E., Kharrat, R., di Luccio, E., Sandoz, G., El Ayeb, M., Darbon, H., De Waard, M., Sabatier, J.-M., *XIIIth World Congress on Animal, Plant and Microbial Toxins*, Paris (France), 2000.

00-3 *Study on the in vitro oxidation/folding of Maurotoxin, a 4 disulfide-bridged scorpion toxin.*

di Luccio, E., Azulay, D.O., Fajloun, Z., Mansuelle, P., Oughideni, R., Sampieri, F., Rochat, H., De Waard, M., Sabatier, J.-M., *XIIIth World Congress on Animal, Plant and Microbial Toxins*, Paris (France), 2000.

00-4 *Chemical synthesis and characterization of Maurocalcine, a scorpion toxin that activates Ca²⁺ release channel/ryanodine receptors.*

Fajloun, Z., Kharrat, R., di Luccio, E., Chen, L., Lecomte, C., Bichet, D., El Ayeb, M., Allen, P.D., Pessah, I.N., Rochat, H., De Waard, M., Sabatier, J.-M., *XIIIth World Congress on Animal, Plant and Microbial Toxins*, Paris (France), 2000.

00-5 *Synthesis, ¹H-NMR structure and activity of a three disulfide-bridged Maurotoxin analog designed to restore the consensus motif of scorpion toxins.*

Fajloun, Z., Ferrat, G., Carlier, C., Fathallah, M., Lecomte, C., Sandoz, G., di Luccio, E., Mabrouk, K., Legros, C., Darbon, H., Rochat, H., Sabatier, J.-M., De Waard, M., *XIIIth World Congress on Animal, Plant and Microbial Toxins*, Paris (France), 2000.

00-6 *Kaliootoxin improves experimental autoimmune encephalomyelitis and inhibits T cell activation.*

Beeton, C., Barbaria, J., Devaux, J., Benoliel, A.M., Gola, M., Sabatier, J.-M., Bernard, D., Crest, M., Beraud, E., *XIIIth World Congress on Animal, Plant and Microbial Toxins*, Paris (France), 2000.

00-7 *Maurotoxine de scorpion réticulée par 4 ponts disulfure.*

Sabatier, J.-M., *User Meeting Proteomics*, Conférencier invité, Applied Biosystems, Paris (France), 2000.

00-8 *Immunosuppression of experimental auto-immune encephalomyelitis (EAE) by selective blocking of K⁺ channels.*

Beeton, C., Wulff, H., Barbaria, J., Crest, C., Sabatier, J.-M., Pennington, M., Chalan, M., Bernard, D., Chandy, K.G., Béraud, E., *Conférences François Lhermitte*, 10^{ème} Réunion de l'ARSEP, Paris (France), 2000.

99-1 *Synthèse chimique et étude des relations structure-activité de la Ts κ, une nouvelle toxine de scorpion active sur les canaux SK.*

Lecomte, C., Blanc, E., Legros, C., Darbon, H., Martin-Eauclaire, M.-F., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *11ème Réunion Peptides et Protéines*, Aussois (France), 1999.

99-2 *Study of the mode of action of SPC3, an anti-HIV peptide under clinical trial.*

Barbouche, R., Fenouillet, E., Papandréou, M.-J., Miquelis, R., Kiény, M.-P., Sabatier, J.-M., *11ème Réunion Peptides et Protéines*, Aussois (France), 1999.

99-3 *A multibranched peptide construct encompassing the cleavage sequence of the HIV envelope precursor alters Env processing and blocks cell/virus membrane fusion, hence HIV infectivity.*

Barbouche, R., Sabatier, J.-M., Fenouillet, E., *11ème Réunion Peptides et Protéines*, Aussois (France), 1999.

- 99-4 **Obtention d'anticorps monoclonaux neutralisant les neurotoxines du venin du scorpion *Androctonus australis Hector*.**
Clot-Faybesse, O., Juin, M., Mabrouk, K., Sabatier, J.-M., Rochat, H., Devaux, C., 11^{ème} Réunion Peptides et Protéines, Aussois (France), 1999.
- 99-5 **Synthèse chimique et caractérisation pharmacologique de la Maurocalcine, une toxine de scorpion active sur les canaux calcium.**
Fajloun, Z., Kharrat, R., Carlier, E., Lecomte, C., Canarelli, S., Rochat, H., Van Rietschoten, J., De Waard, M., Sabatier, J.-M., 11^{ème} Réunion Peptides et Protéines, Aussois (France), 1999.
- 99-6 **SPC3, an HIV-derived multibranch peptide, triggers a Cl^- conductance in *Xenopus oocytes*.**
De Waard, M., Carlier, E., Manrique, C., Fajloun, Z., Mabrouk, K., Sabatier, J.-M., 11^{ème} Réunion Peptides et Protéines, Aussois (France), 1999.
- 99-7 **Inhibition of HIV infection: structure-activity study on synthetic multiple branch peptide from a cytoplasmic domain of the envelope glycoprotein gp41.**
Mabrouk, K., Moulard, M., Rochat, H., Sabatier, J.-M., Van Rietschoten, J., 11^{ème} Réunion Peptides et Protéines, Aussois (France), 1999.
- 99-8 **Synthèse et étude pharmacologique d'une nouvelle toxine de scorpion active sur les canaux calcium: la Maurocalcine.**
Fajloun, Z., Kharrat, R., Carlier, E., Lecomte, C., Canarelli, S., Rochat, H., Van Rietschoten, J., De Waard, M., Sabatier, J.-M., 3^{ème} Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires, Marseille (France), 1999.
- 99-9 **Activité antivirale de nouvelles constructions peptidiques dérivées de la glycoprotéine transmembranaire gp41 du VIH.**
Mabrouk, K., Moulard, M., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., 3^{ème} Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires, Marseille (France), 1999.
- 99-10 **La boucle I-II de la sous-unité alpha1 des canaux Ca^{2+} contient un signal de rétention intracellulaire beta-dépendant.**
Bichet, D., Cornet, V., Carlier, E., Geib, S., Sabatier, J.-M., Hoshi, T., De Waard, M., 3^{ème} Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires, Marseille (France), 1999.
- 99-11 **La première boucle cytoplasmique de la sous-unité alpha 1 des canaux calcium contient un signal de rétention, dépendant de la sous-unité beta, pour le compartiment endoplasmique.**
Bichet, D., Cornet, V., Carlier, E., Geib, S., Lecomte, C., Sabatier, J.-M., Hoshi, T., Mori, Y., De Waard, M., 4^{ème} Colloque des Neurosciences, Marseille (France), 1999.
- 99-12 **Mécanismes d'action cellulaire de SPC3, un peptide inhibiteur de l'infection par le VIH.**
Carlier, E., Mabrouk, K., Sabatier, J.-M., De Waard, M., 4^{ème} Colloque des Neurosciences, Marseille (France), 1999.
- 99-13 **Déterminants structuraux de la maurotoxine responsables de l'inhibition des canaux de type Shaker.**
Carlier, E., Geib, S., Mabrouk, K., Fajloun, Z., Bichet, D., Darbon, H., Rochat, H., Sabatier, J.-M., De Waard, M., Colloque "Canaux Ioniques", 10^{ème} Edition, La Londe les Maures (France), 1999.
- 99-14 **La Maurotoxine : Etude des relations structure-fonction à l'aide d'analogues synthétiques**
Sabatier, J.-M., 7^{ème} Rencontres en Toxinologie, "Avancées Biotechnologiques Associées aux Toxines", Paris (France), 1999 (Conférencier invité; Résumé des travaux publié dans la revue *Toxicon*).
- 99-15 **Thérapie de l'encephalomyélite autoimmune expérimentale (EAE) par un bloqueur des canaux K^+ voltage-dépendants (Kv) : la kaliotoxine.**

Beeton, C., Barbaria, J., Devaux, J., Bernard, D., Sabatier, J.-M., Gola, M., Crest, C., Béraud, E., *Congrès de la Société Française d'Immunologie*, Lille (France), 1999.

99-16 *Thérapie de l'encephalomyélite autoimmune expérimentale (EAE) par la kaliotoxine, un bloqueur des canaux K⁺ voltage-dépendants (Kv).*

Beeton, C., Barbaria, J., Devaux, J., Bernard, D., Giraud, P., Sabatier, J.-M., Gola, M., Crest, C., Béraud, E., *Conférences François Lhermitte*, 9^{ème} Réunion de l'ARSEP, Paris (France), 1999.

98-1 *Structure-activity relationships of Ts κ , a scorpion toxin acting on small conductance calcium-activated K⁺ channels.*

Legros, C., Lecomte, C., Blanc, E., Darbon, H., Sabatier, J.-M., Martin-Eauclaire, M.-F., *Forum of European Neuroscience*, Berlin (Germany), 1998.

Eur. J. Neuroscience 10 : 6432 Suppl. 10, 1998.

98-2 *La Maurotoxine inhibe les canaux K⁺ de type shaker B exprimés dans des ovocytes de Xénope.*

Carlier, E., Geib, S., Bichet, D., Hoshi, T., Sabatier, J.-M., De Waard, M., *Colloque "Canaux Ioniques"*, 9^{ème} Edition, La Londe les Maures (France), 1998.

98-3 *The I-II loop of calcium channel $\alpha 1$ subunit contains an ER retention signal.*

Bichet, D., Cornet, V., Carlier, S., Geib, S., Sabatier, J.-M., Hoshi, T., De Waard, M., *Colloque "Canaux Ioniques"*, 9^{ème} Edition, La Londe les Maures (France), 1998.

98-4 *Synthèse et caractérisation de la Ts κ , une nouvelle toxine courte de scorpion active sur les canaux K⁺ activés par le Ca²⁺ sensibles à l'apamine.*

Lecomte, C., Blanc, E., Legros, C., Fajloun, Z., Darbon, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., Sabatier, J.-M., *6^{ème} Rencontre en Toxinologie*, Paris (France), 1998. Résumé publié dans la revue *Toxicon*, 37, 1227 (1999).

98-5 *La maurocalcine: un nouveau type de repliement chez les toxines de scorpion.*

Mosbah, A., Kharrat, R., Renisio, J.-G., Blanc, E., Sabatier, J.-M., El Ayeb, M., Darbon, H., *6^{ème} Rencontre en Toxinologie*, Paris (France), 1998. Résumé publié dans la revue *Toxicon*, 37, 1233 (1999).

97-1 *Synthesis and characterization of Leiurotoxin I analogs lacking one disulfide bridge.*

Sabatier, J.-M., Lecomte, C., Mabrouk, K., Fremont, V., Darbon, H., Oughideni, R., Canarelli, S., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., *Fourth Forum on Peptides & Proteins*, Montpellier (France), 1997.

97-2 *Chemical synthesis and characterization of a short scorpion toxin cross-linked by four disulfide bridges, the Maurotoxin.*

Kharrat, R., Mabrouk, K., Crest, M., Darbon, H., Lecomte, C., Oughideni, R., Martin-Eauclaire, M.-F., Jacquet, G., El Ayeb, M., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *Fourth Forum on Peptides & Proteins*, Montpellier (France), 1997.

97-3 *Antiviral activity of polymeric construction of a peptide derived from the human immunodeficiency virus envelope transmembrane glycoprotein gp41.*

Mabrouk, K., Moulard, M., Fenouillet, E., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *Fourth Forum on Peptides & Proteins*, Montpellier (France), 1997.

97-4 *Usefulness of a non-toxic analog to elicit neutralizing poly- and monoclonal antibodies against scorpion toxin.*

Devaux, C., Clot-Faybesse, O., Juin, M., Mabrouk, K., Sabatier, J.-M., El Ayeb, M., Rochat, H., *Fourth Forum on Peptides & Proteins*, Montpellier (France), 1997.

97-5 Determination of the three-dimensional structure of Ts κ scorpion toxin, from *Tityus Serrulatus*, by ^1H two-dimensional NMR spectroscopy.

Blanc, E., Sabatier, J.-M., Legros, C., Martin-Eauclaire, M.-F., Darbon, H., *Fourth Forum on Peptides & Proteins*, Montpellier (France), 1997.

97-6 Etude de l'implication des ponts disulfure dans la structure et l'activité de la leurotoxine I à l'aide d'analogues synthétiques.

Lecomte, C., Sabatier, J.-M., Mabrouk, K., Darbon, H., Oughideni, R., Canarelli, S., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., *2ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 1997.

97-7 Activité antivirale des constructions peptidiques multibranchées (SPCs) dérivées de la glycoprotéine transmembranaire gp41 de l'enveloppe du VIH.

Mabrouk, K., Moulard, M., Fenouillet, E., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *2ème Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 1997.

97-8 Usefulness of a non-toxic analog to elicit neutralizing poly- and monoclonal antibodies against scorpion toxin.

Devaux, C., Clot-Faybesse, O., Juin, M., Mabrouk, K., Sabatier, J.-M., El Ayeb, M., Rochat, H., *12th World Congress on Animal, Plant and Microbial Toxins-IST*, Mexico (Mexique), 1997.

97-9 Characterization of Ts κ , a peptide from *Tityus serrulatus* venom which is a new ligand of the apamin-binding site.

Legros, C., Lecomte, C., Blanc, E., Darbon, H., Sabatier, J.-M., Martin-Eauclaire, M.-F., *Int. Potassium Channel Conference*, Ulm (Germany), 1997.

97-10 Solution structure of scorpion neurotoxins: toward a new model of interaction with potassium channels.

Blanc, E., Frémont, V., Lecomte, C., Martin-Eauclaire, M.-F., Sabatier, J.-M., Darbon, H., *5ème Rencontres en Toxinologie*, Paris (France), 1997. Résumé publié dans la revue *Toxicon*, **36**, 1732 (1998).

96-1 Anti-HIV activity of multibranch peptides derived from Env.

Sabatier, J.-M., Mabrouk, K., Moulard, M., Rochat, H., Van Rietschoten, J., Fenouillet, E., *36th Interscience Conference on Antimicrobial Agents and Chemotherapy*, New-Orleans (USA), 1996.

96-2 Maurotoxin, a short scorpion toxin with four disulfide bridges, active on apamin-sensitive K^+ channels and voltage-gated K^+ channels.

Kharrat, R., El Ayeb, M., Crest, M., Mansuelle, P., Martin-Eauclaire, M.-F., Van Rietschoten, J., Sabatier, J.-M., Rochat, H., *4th Annual Neuropharmacology Conference*, Washington (USA), 1996.

96-3 L'activité de la Maurotoxine sur les canaux K^+ dépend de l'intégrité du térapeptide C-terminal.

Ben Khalifa, R., Crest, M., Lecomte, C., Pelhate, M., El Ayeb, M., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *7ème Congrès sur les Canaux Ioniques*, La Londe-les-Maures (France), 1996.

96-4 Anti-HIV activity of multibranch peptides derived from Env.

Sabatier, J.-M., Mabrouk, K., Moulard, M., Rochat, H., Van Rietschoten, J., Fenouillet, E., *24th Eur. Pept. Symp.*, Edinburgh (UK), 1996.

96-5 Multidisciplinary approach for immunoprevention of scorpion envenoming.

El Ayeb, M., Zenouaki, I., Bouhaouala, B., Karaoui, H., Kharrat, R., Ducancel, F., Boulain, J.-C., Ménez, A., Sabatier, J.-M., Mabrouk, K., Devaux, C., Van Rietschoten, J., Rochat, H., *First International Congress on Envenomations and their Treatments*, C. Bon and M. Goyffon Eds, 1996, 197-210.

96-6 Importance of the fourth disulfide bridge in the maurotoxin structure and activity.

Ben Khalifa, R., Crest, M., Pelhate, M., Kharrat, R., Darbon, H., El Ayeb, M., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *4ème Journées des Rencontres en Toxinologie*, Paris (France), 1996. Résumé publié dans la revue *Toxicon*, 35, 1660-1661 (1997).

96-7 Neutralizing polyclonal and monoclonal antibodies against scorpion toxin obtained by using a non-toxic analogue.

Devaux, C., Clot-Faybesse, O., Juin, M., Mabrouk, K., Sabatier, J.-M., El Ayeb, M., Rochat, H., *4ème Journées des Rencontres en Toxinologie*, Paris (France), 1996. Abstract published in *Toxicon*, 35, 1663-1664 (1997).

96-8 The first chemical synthesis of a short scorpion toxin cross-linked by four disulfide bridges, maurotoxin.

Kharrat, R., Mabrouk, K., Crest, M., Darbon, H., Oughideni, R., Martin-Eauclaire, M.-F., Jacquet, G., El Ayeb, M., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *4ème Journées des Rencontres en Toxinologie*, Paris (France), 1996. Abstract published in *Toxicon*, 35, 1666 (1997).

95-1 Multi-branched V3 peptides inhibit HIV-1 infection in human lymphocytes and macrophages.

Yahi, N., Fantini, J., Mabrouk, K., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *9ème Réunion des Peptides et Protéines*, Aussois (France), 1995.

95-2 Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of HIV-1 gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.

Fantini, J., Sabatier, J.-M., Yahi, N., *9ème Réunion des Peptides et Protéines*, Aussois (France), 1995.

95-3 Lethal neurotoxicity in mice and cytotoxic effect of N-terminal domain of HIV-1 p18 protein.

Cestèle, S., Benjouad, A., Sabatier, J.-M., Romi, R., Guieu, R., Rochat, H., Van Rietschoten, J., Mabrouk, K., *9ème Réunion des Peptides et Protéines*, Aussois (France), 1995.

95-4 Leiurotoxin I, a scorpion toxin specific for Ca^{2+} -activated K^+ channels: Structure-activity analysis using synthetic analogs.

Fremont, V., Martin-Eauclaire, M.-F., Mabrouk, K., Crest, M., Darbon, H., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *9ème Réunion des Peptides et Protéines*, Aussois (France), 1995.

95-5 Synthetic multimeric peptides derived from the V3 loop of HIV-1 gp120 bind to GalCer and block HIV-1 infection in CD4-negative mucosal epithelial cells.

Yahi, N., Sabatier, J.-M., Baghdiguian, S., Gonzalez-Scarano, F., Fantini, J., *Keystone Symposia on HIV Pathogenesis*, Keystone (USA), 1995.

J. Cell Biochem.: 246 Suppl. 21B April 2, 1995.

95-6 Etude des relations structure-activité de P05, une toxine de scorpion active sur les canaux K^+ activés par le Ca^{2+} .

Sabatier, J.-M., Zerrouk, H., Mabrouk, K., Darbon, H., Benslimane, A., Rochat, H., Martin-Eauclaire, F., Van Rietschoten, J., *Archs. Inst. Pasteur Tunis*, 4ème Réunion du Réseau INSERM Nord-Sud N° 492NS6, "Envenimation Scorpionique et Ophidienne", Tunis (Tunisia), 72, pp 196-197, 1995.

95-7 Toxines de scorpion: Analyse de la réponse humorale à différents immunogènes.

Devaux, C., Granier, C., Juin, M., Sabatier, J.-M., Mabrouk, K., Van Rietschoten, J., Rochat, H., *Archs. Inst. Pasteur Tunis*, 4ème Réunion du Réseau INSERM Nord-Sud N° 492NS6, "Envenimation Scorpionique et Ophidienne", Tunis (Tunisia), 72, p 209, 1995.

95-8 Utilisation des Abu-8 toxines comme modèles de toxines vaccinales.

Zenouaki, I., Kharrat, R., Karoui, H., El Ayeb, M., Sabatier, J.-M., Mabrouk, K., Van Rietschoten, J., Rochat, H., *Archs. Inst. Pasteur Tunis*, 4ème Réunion du Réseau INSERM Nord-Sud N° 492NS6, "Envenimation Scorpionique et Ophidienne", Tunis (Tunisia), 72, pp 212, 1995.

95-9 Potentialisation d'une activité biologique par branchement multimérique: Exemple de SPC3, un peptide inhibiteur de l'infection des cellules-cibles par le VIH.

Yahi, N., Fantini, J., Mabrouk, K., Rochat, H., Sabatier, J.-M., Van Rietschoten, J., *GESA XXV*, St Valery-en-Caux (France), 1995.

95-10 Multi-branched V3 peptides inhibit HIV-1 infection in human lymphocytes and macrophages.

Yahi, N., Fantini, J., Mabrouk, K., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *1er Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 1995.

95-11 SPC3, a synthetic peptide derived from the V3 domain of HIV-1 gp120, inhibits HIV-1 entry into CD4⁺ and CD4⁻ cells by two distinct mechanisms.

Yahi, N., Fantini, J., Baghdiguian, S., Mabrouk, K., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *1er Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 1995.

95-12 Relations structure-activité des toxines actives sur les canaux de type KCa sensibles à l'apamine.

Fremont, V., Zerrouk, H., Darbon, H., Sabatier, J.-M., Van Rietschoten, J., Rochat, H., Martin-Eauclaire, M.-F., *1er Colloque de l'Institut Fédératif Jean Roche de Biologie des Interactions Cellulaires*, Marseille (France), 1995.

94-1 Multi-branched peptides based on the HIV-1 V3 loop consensus motif inhibit HIV-1 and HIV-2 infection in CD4⁺ and CD4⁻ cells.

Fantini, J., Yahi, N., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *XXI Forum des Jeunes Chercheurs*, Reims (France), 1994.

94-2 Lethal neurotoxicity in mice and cytotoxic effect of N-terminal domain of HIV-1 p18 protein.

Cestèle, S., Benjouad, A., Romi, R., Sabatier, J.-M., Guieu, R., Rochat, H., Van Rietschoten, J., Mabrouk, K., *XXI Forum des Jeunes Chercheurs*, Reims (France), 1994.

94-3 Current events in the development of a new class of anti-retrovirals: the SPC.

Fantini, J., Yahi, N., Mabrouk, K., Van Rietschoten, J., Rochat, H., Sabatier, J.-M., *XIIth Mediterranean Symposium on HIV infection*, Toulon (France), 1994.

94-4 Multi-branched peptide constructs (MBPC) of the V3 loop of gp120 inhibit human immunodeficiency virus infection.

Benjouad, A., Fenouillet, E., Chapuis, F., Gluckman, J.-C., Sabatier, J.-M., *Xth International Conference on AIDS*, Yokohama (Japan), 1994.

94-5 Préparation d'anatoxines de venins de scorpion et essais de protection sur modèles animaux.

Kharrat, R., Zenouaki, I., Sabatier, J.-M., Belasfar, Z., Miled, K., Karoui, H., Van Rietschoten, J., Dellagi, K., Rochat, H., El Ayeb, M., *Archs. Inst. Pasteur Tunis*, 71, 473-476 (1994).

93-1 Study on P05, a new leurotoxin I-like scorpion toxin.

Sabatier, J.-M., Zerrouk, H., Darbon, H., Mabrouk, K., Benslimane, A., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., *XIth European Meeting of the International Society of Toxinology*, Arezzo (Italia), 1993.

93-2 Leurotoxin I, a scorpion toxin specific for Ca²⁺-activated K⁺ channels: Structure-activity analysis using synthetic analogs.

Sabatier, J.-M., Fremont, V., Mabrouk, K., Crest, M., Darbon, H., Rochat, H., Van Rietschoten, J., Martin-Eauclaire, M.-F., *XIth European Meeting of the International Society of Toxinology*, Arezzo (Italia), 1993.

93-3 Caractérisation des toxines de scorpion du genre *Androctonus* actives sur les canaux K⁺.

Zerrouk, H., Laraba, F., Crest, M., Sabatier, J.-M., Rochat, H., Martin-Eauclaire, M.-F., *1ère Journée des Rencontres de Toxinologie*, Paris (France), 1993.

93-4 Cytotoxicity on lymphocytes of Tat from human immunodeficiency virus type 1.

Benjouad, A., Mabrouk, K., Moulard, M., Rochat, H., Van Rietschoten, J., Sabatier, J.-M., *IXth International Conference on AIDS*, Berlin (Germany), 1993.

93-5 Epitope mapping of 21 synthetic peptides derived from human T-cell lymphotropic virus type 1 and type 2 proteins.

Moncan, T., Ledoux, D., Sabatier, J.-M., Hoffenbach, A., Rabillon, V., Somme, G., Van Rietschoten, J., *IXth International Conference on AIDS*, Berlin (Germany), 1993.

93-6 Evaluation of a new synthetic peptides Elisa test for the detection of anti-HTLV-1 and anti-HTLV-2 antibodies.

Ledoux, D., Moncan, T., Sabatier, J.-M., Defendini, M.-L., Van Rietschoten, J., Rabillon, V., Hoffenbach, A., Somme, G., *IXth International Conference on AIDS*, Berlin (Germany), 1993.

93-7 Study on P05, a new leurotoxin I-like scorpion toxin.

Sabatier, J.-M., Zerrouk, H., Darbon, H., Mabrouk, K., Benslimane, A., Rochat, H., Martin-Eauclaire, M.-F., Van Rietschoten, J., *IIIrd Forum on Peptides and Proteins*, Biarritz (France), 1993.

92-1 Early detection of anti-HCV antibodies in a rapid immunofiltration assay using synthetic peptides.

Tordjman, M., Lunel Fabiani, F., Fontan, G., About, D., Blanc, C., Sabatier, J.-M., Rabillon, V., Hoffenbach, A., Van Rietschoten, J., Somme, G., *Hepatitis C Virus and Related Viruses*, Venezia (Italy), 1992.

92-2 Detection of anti-HCV antibodies with an enzyme immunoassay using synthetic peptides.

About, D., Sabatier, J.-M., Delaroche, C., Tordjman, M., Defendini, M.-L., Rabillon, V., Hoffenbach, A., Maisonneuve, P., Van Rietschoten, J., Somme, G., *Hepatitis C Virus and Related Viruses*, Venezia (Italy), 1992.

92-3 L'utilisation des peptides synthétiques en immunodiagnostic et immunothérapie.

Van Rietschoten, J., Sabatier, J.-M., *Biospot N°5* (lettre d'information scientifique des laboratoires Clonatec), 1992.

91-1 Localisation à l'aide de peptides synthétiques des épitopes B et T de la protéine Gag p25 du virus de l'immunodéficience humaine de type 1 (VIH-1).

Mabrouk, K., Van Rietschoten, J., Benjouad, A., Rochat, H., Sabatier, J.-M., Bahraoui, E., *7ème Réunion Peptides*, Aussois (France), 1991.

91-2 Evidence for neurotoxic activity of Tat from human immunodeficiency virus type 1.

Sabatier, J.-M., Vives, E., Mabrouk, K., Benjouad, A., Rochat, H., Duval, A., Hue, B., Van Rietschoten, J., Bahraoui, E., *7ème Réunion Peptides*, Aussois (France), 1991.

91-3 Evidence for neurotoxic activity of Tat from human immunodeficiency virus type 1.

Sabatier, J.-M., Vives, E., Mabrouk, K., Benjouad, A., Rochat, H., Duval, A., Hue, B., Van Rietschoten, J., Bahraoui, E., *XIX Forum des Jeunes Chercheurs*, Tours (France), 1991.

91-4 Evidence for neurotoxic activity of Tat from human immunodeficiency virus type 1.

Sabatier, J.-M., Vives, E., Mabrouk, K., Benjouad, A., Rochat, H., Duval, A., Hue, B., Van Rietschoten, J., Bahraoui, E., *VII International Conference on AIDS*, Florence (Italia), 1991.

91-5 Hepatitis B core antigen mapping by synthetic peptides.

Tordjman, M., Fontan, G., Van Rietschoten, J., Sabatier, J.-M., Trepo, C., Somme, G., *European Virology Meeting*, Strasbourg (France), 1991.

89-1 Prevalence of anti-Nef positive sera in HIV-infected patients: mapping of the major epitopes of Nef-protein using synthetic peptides.

Sabatier, J.-M., Van Rietschoten, J., Granier, C., Gluckman, J.-C., Montagnier, L., Bahraoui, E., *V International Conference on AIDS*, Montréal (Canada), 1989.

89-2 Prevalence of anti-Nef positive sera in HIV-infected patients: mapping of the major epitopes of Nef-protein using synthetic peptides.

Sabatier, J.-M., Van Rietschoten, J., Granier, C., Gluckman, J.-C., Montagnier, L., Bahraoui, E., *IV International Conference on AIDS and Associated Cancers in Africa*, Marseille (France), 1989.

89-3 Mapping of T- and B-cell epitopes of HIV-1 Nef-protein in immunized chimpanzees.

Gluckman, J.-C., Yagello, M., Sabatier, J.-M., Billaud, J.-N., Girard, M., Bahraoui, E., *7 th International Congress of Immunology*, Berlin (West Germany), 1989.

89-4 Mapping of T- and B-cell epitopes of HIV-1 Nef-protein in immunized chimpanzees.

Gluckman, J.-C., Yagello, M., Sabatier, J.-M., Billaud, J.-N., Girard, M., Bahraoui, E., *V International Conference on AIDS*, Montréal (Canada), 1989.

89-5 Caractérisation d'anticorps de spécificité prédéterminée dirigés contre les canaux Na⁺ de cerveau de rat.

Levêque, C., Massacrier, A., Dargent, B., Cau, P., Sabatier, J.-M., Céard, B., Van Rietschoten, J., Granier, C., *Société Française de Neurosciences*, Montpellier, France, 1989.

88-1 Antigenicity of conserved regions and accessibility of the N- and C-terminal fragments of HIV-1 and HIV-2 large glycoprotein.

Bahraoui, E., Clerget, B., Granier, C., Van Rietschoten, J., Sabatier, J.-M., Labbé-Jullié, C., Guétard, D., Chamaret, S., Rochat, H., Gluckman, J.-C., Montagnier, L., *IV International Conference on AIDS*, Stockholm (Sweden), 1988, Book II, p 117.

88-2 Antigenicity of conserved regions and accessibility of the N- and C-terminal fragments of HIV-1 and HIV-2 large glycoprotein.

Bahraoui, E., Clerget, B., Granier, C., Van Rietschoten, J., Sabatier, J.-M., Labbé-Jullié, C., Guétard, D., Chamaret, S., Rochat, H., Gluckman, J.-C., Montagnier, L., *III International Conference on AIDS and Associated Cancers in Africa*, Arusha (Tanzania), 1988, p 43.

88-3 Antigénicité des régions conservées de l'enveloppe de HIV-1 et HIV-2 et étude de l'interaction gp110-CD4.

Bahraoui, E., Clerget, B., Granier, C., Sabatier, J.-M., Van Rietschoten, J., Rochat, H., Gluckman, J.-C., Montagnier, L., *6ème Ecole Franco-Africaine de Biologie Moléculaire*, Djerba (Tunisia), 1988, pp. 188-189.

86-1 Utilisation des Fmoc-acides aminés pour la synthèse chimique de segments protégés.

Sabatier, J.-M., Tessier, M., Granier, C., Van Rietschoten, J., *5ème Réunion Peptides*, Le Touquet, France, 1986.

86-2 Protocole alternatif de synthèse peptidique en phase solide par les Fmoc-acides aminés.

Fourquet, P., Sabatier, J.-M., Granier, C., Van Rietschoten, J., *5ème Réunion Peptides*, Le Touquet, France, 1986.